{
  "A98G": {
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,E138A": {
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,E138A,G190A,M230L": {
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,E138A,G190E": {
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190EQ": "G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,E138A,V179E,G190S": {
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,E138A,Y181I": {
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,E138G,G190A": {
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,E138G,V179E,Y188L": {
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,E138G,Y188L": {
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,E138K,V179E": {
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,E138Q": {
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,E138Q,G190A": {
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,F227L": {
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,G190A": {
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,G190A,F227L": {
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,G190A,K238T": {
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,G190C": {
    "RT190CTV": "G190C/T/V are rare non-polymorphic mutations that cause high-level resistance to NVP and EFV. Their effects on ETR, RPV, and DOR susceptibility are not known.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,G190E": {
    "RT190EQ": "G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,G190E,H221Y": {
    "RT190EQ": "G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,G190Q": {
    "RT190EQ": "G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,G190S": {
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,G190S,H221Y": {
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,G190S,K238T": {
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,G190T": {
    "RT190CTV": "G190C/T/V are rare non-polymorphic mutations that cause high-level resistance to NVP and EFV. Their effects on ETR, RPV, and DOR susceptibility are not known.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,H221Y": {
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,E138A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,E138A,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,E138A,G190A,K238T": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,E138A,G190S": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,E138A,Y181C": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,E138A,Y181C,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,E138G": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,E138G,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,E138G,G190S": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,E138G,Y181C,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,E138K,G190E": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT190EQ": "G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,E138K,V179D,Y181C,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,E138K,Y181C": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,E138Q": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,E138Q,Y181C": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,E138R,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138R": "E138R is a rare non-polymorphic accessory mutation selected in vitro by RPV. It is associated with 2 to 3-fold reduced susceptibility to ETR and RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,G190A,K238T": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,G190A,P225H": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,G190C": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT190CTV": "G190C/T/V are rare non-polymorphic mutations that cause high-level resistance to NVP and EFV. Their effects on ETR, RPV, and DOR susceptibility are not known.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,G190S": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,K103H,V106I,Y181C,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103H": "K103H is a rare non-polymorphic mutation that causes high-level resistance to NVP and EFV.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,K103N,E138A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,K103N,V106A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,K103N,V106I,Y181C,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,K103N,V108I,Y181C,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,K103N,Y181C,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,K103N,Y181C,G190A,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,K103N,Y181F,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181FSG": "Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,K103S,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,K103T,V108I,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103T": "K103T is an extremely rare non-polymorphic mutation that appears to cause intermediate/high-level resistance to NVP. It has little if any effect on EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,M184I,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT184VI": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,V106A,Y181C,G190A,F227L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,V106I,E138A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,V106I,E138Q,Y181C,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,V106I,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,V106I,V108I,E138A,V179F,Y181C,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT179F": "V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,V106I,V108I,Y181C,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,V106I,V108I,Y181C,G190A,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,V106I,V108I,Y181V,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,V106I,Y181C,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,V106M,E138A,F227L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,V106M,V108I": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,V106M,Y181C,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,V108I,E138A,H221Y,M230L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,V108I,E138A,Y181C": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,V108I,E138A,Y181I,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,V108I,E138K,Y181C,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,V108I,E138K,Y181C,G190A,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,V108I,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,V108I,V179D,Y181C,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,V108I,V179T,Y181C,G190A,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179T": "V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,V108I,Y181C": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,V108I,Y181C,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,V108I,Y181C,G190A,F227L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,V108I,Y181C,G190A,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,V108I,Y181C,G190A,H221Y,F227L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,V108I,Y181C,G190A,K238T": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,V108I,Y181C,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,V108I,Y181C,P225H": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,V108I,Y181C,Y188L,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,V108I,Y181S,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181FSG": "Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,V108I,Y181S,G190A,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181FSG": "Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,V108I,Y181V": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,V179D,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,V179D,Y181C,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,V179F,Y181C,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT179F": "V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,V179F,Y181F,G190S": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT179F": "V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181FSG": "Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,Y181C": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,Y181C,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,Y181C,G190A,F227L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,Y181C,G190A,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,Y181C,G190A,H221Y,F227L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,Y181C,G190A,K238T": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,Y181C,G190A,P225H": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,Y181C,G190C": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190CTV": "G190C/T/V are rare non-polymorphic mutations that cause high-level resistance to NVP and EFV. Their effects on ETR, RPV, and DOR susceptibility are not known.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,Y181C,G190S": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,Y181C,G190S,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,Y181C,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,Y181C,M184I": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT184VI": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,Y181C,M184I,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT184VI": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,Y181C,M184I,G190A,F227L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT184VI": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,Y181C,N348I": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101E,Y181V,G190A,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101H,E138A,Y181C,G190A": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101H,G190A": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101H,G190S": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101H,K103H,Y181C,G190A,H221Y": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT103H": "K103H is a rare non-polymorphic mutation that causes high-level resistance to NVP and EFV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101H,V106I,V108I,V179T,Y181C,G190S": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179T": "V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101H,V108I,V179T,Y181C,G190S": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179T": "V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101H,V108I,Y181C,G190A": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101H,V108I,Y181C,H221Y": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101H,V108I,Y181C,H221Y,F227L": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101H,Y181C": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101H,Y181C,G190A": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101H,Y181C,G190A,H221Y": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101H,Y188L": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101P": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101P,G190A": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101P,K103N": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101P,V106I,Y188C": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K101P,V179D": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103H,V108I,Y181C,G190A": {
    "RT103H": "K103H is a rare non-polymorphic mutation that causes high-level resistance to NVP and EFV.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103H,V108I,Y181C,G190A,H221Y": {
    "RT103H": "K103H is a rare non-polymorphic mutation that causes high-level resistance to NVP and EFV.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103H,Y181C,G190A": {
    "RT103H": "K103H is a rare non-polymorphic mutation that causes high-level resistance to NVP and EFV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103H,Y181C,G190A,H221Y": {
    "RT103H": "K103H is a rare non-polymorphic mutation that causes high-level resistance to NVP and EFV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,E138A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,E138A,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,E138A,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,E138A,Y188F": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT188F": "Y188F is a rare non-polymorphic NNRTI-associated mutation that is usually present as part of an electrophoretic mixture. It appears to represent a transitional mutation between Y and L.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,E138A,Y188L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,E138G": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,E138G,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,E138K": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,E138Q": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,E138Q,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,E138Q,V179L,Y181C,H221Y,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT179L": "V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,E138Q,Y181C": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,E138Q,Y318F": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,G190A,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,G190S": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,H221Y,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,H221Y,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,K238N": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,K238T,Y318F": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,P225H,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,P225H,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,P225H,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V106A,E138Q": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V106A,G190A,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V106A,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V106A,Y181C": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V106A,Y181C,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V106A,Y181C,G190A,H221Y,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V106I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V106I,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V106I,V108I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V106I,V108I,Y181C,G190A,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V106I,Y181C": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V106I,Y181C,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V106M": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V106M,V108I,Y188C": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V106M,V179D,Y181C,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V106M,Y188L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V108I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V108I,E138G": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V108I,E138G,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V108I,E138G,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V108I,E138G,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V108I,E138Q,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V108I,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V108I,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V108I,G190A,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V108I,G190S": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V108I,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V108I,H221Y,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V108I,H221Y,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V108I,H221Y,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V108I,H221Y,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V108I,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V108I,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V108I,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V108I,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V108I,P225H,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V108I,V179E,Y181C,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V108I,V179F,Y181C,G190A,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179F": "V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V108I,V179F,Y181C,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179F": "V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V108I,Y181C": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V108I,Y181C,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V108I,Y181C,G190A,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V108I,Y181C,G190A,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V108I,Y181C,G190S": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V108I,Y181C,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V108I,Y181C,H221Y,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V108I,Y181C,H221Y,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V108I,Y181C,H221Y,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V108I,Y181C,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V108I,Y181C,Y188L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V108I,Y181C,Y318F": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V108I,Y188L,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V108I,Y318F": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V179E": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V179E,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V179E,P225H,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V179E,Y181C": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V179E,Y181C,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V179E,Y181I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V179F,Y181C": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179F": "V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V179F,Y181C,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179F": "V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,V179T,Y181C,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179T": "V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,Y181C": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,Y181C,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,Y181C,G190A,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,Y181C,G190A,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,Y181C,G190A,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,Y181C,G190A,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,Y181C,G190S": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,Y181C,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,Y181C,K238N": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,Y181C,K238N,Y318F": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,Y181C,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,Y181C,K238T,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,Y181C,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,Y181C,Y188C,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,Y181C,Y188L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,Y181C,Y188L,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,Y181I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,Y181I,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,Y181V": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,Y188H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,Y188L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,Y188L,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103N,Y318F": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103R,V106I,V108I,V179D,Y181C,G190A": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103R,V108I,V179D,H221Y": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103R,V108I,V179D,P225H": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103R,V179D": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103S": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103S,E138Q,V179T,Y181C,G190A": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT179T": "V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103S,G190A": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103S,G190A,P225H": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103S,G190A,P225H,K238T": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103S,G190A,Y318F": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103S,G190S": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103S,K238T": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103S,V106M": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103S,V108I,H221Y": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103S,V179E,Y181C": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103S,Y181C": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103S,Y181C,G190A": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103S,Y181C,G190A,H221Y": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103S,Y181I,H221Y": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103T": {
    "RT103T": "K103T is an extremely rare non-polymorphic mutation that appears to cause intermediate/high-level resistance to NVP. It has little if any effect on EFV susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K103T,G190A": {
    "RT103T": "K103T is an extremely rare non-polymorphic mutation that appears to cause intermediate/high-level resistance to NVP. It has little if any effect on EFV susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,K238T": {
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,L100I": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,L100I,K101E,E138A,G190A,F227L": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,L100I,K101E,K103N,V108I,G190A,F227L,K238T": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,L100I,K101E,M184I,G190A": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT184VI": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,L100I,K101E,V106I,V108I,Y181I,G190A": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,L100I,K101E,V106M,G190A": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,L100I,K101E,V108I,H221Y": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,L100I,K101E,V179D,Y181C,G190S,P225H": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,L100I,K103N": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,L100I,K103N,H221Y": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,L100I,K103N,P225H": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,L100I,K103N,V106I,G190V": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT190CTV": "G190C/T/V are rare non-polymorphic mutations that cause high-level resistance to NVP and EFV. Their effects on ETR, RPV, and DOR susceptibility are not known.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,L100I,K103N,V108I": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,L100I,K103N,V108I,Y181C,G190A,H221Y": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,L100I,K103N,V179F,Y181C,G190A,N348I": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179F": "V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,L100I,K103N,Y181C": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,L100I,K103N,Y181C,H221Y": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,L100I,K103R,V106I,V179D,Y181C,G190A": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,L100I,K103R,V179D,G190A": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,L100I,K103S": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,L100I,K103T,Y181C": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103T": "K103T is an extremely rare non-polymorphic mutation that appears to cause intermediate/high-level resistance to NVP. It has little if any effect on EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,L100I,V106M,Y181C,G190A": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,L100I,V108I,Y181I": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,L100I,V179D,G190A": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,L100I,V179D,Y181I,H221Y": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,L100I,Y188L": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,L100I,Y188L,H221Y": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,L100V": {
    "RT100V": "L100I is a non-polymorphic mutation that usually occurs with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. L100V is a rare non-polymorphic mutation with low / intermediate resistance to EFV, NVP, and RPV.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,L100V,K103N,H221Y,K238T": {
    "RT100V": "L100I is a non-polymorphic mutation that usually occurs with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. L100V is a rare non-polymorphic mutation with low / intermediate resistance to EFV, NVP, and RPV.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,L100V,K103N,P225H": {
    "RT100V": "L100I is a non-polymorphic mutation that usually occurs with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. L100V is a rare non-polymorphic mutation with low / intermediate resistance to EFV, NVP, and RPV.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,L100V,K103N,V108I,V179E,Y181C": {
    "RT100V": "L100I is a non-polymorphic mutation that usually occurs with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. L100V is a rare non-polymorphic mutation with low / intermediate resistance to EFV, NVP, and RPV.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,L100V,K103N,Y181C,G190A": {
    "RT100V": "L100I is a non-polymorphic mutation that usually occurs with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. L100V is a rare non-polymorphic mutation with low / intermediate resistance to EFV, NVP, and RPV.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,L100V,Y188L": {
    "RT100V": "L100I is a non-polymorphic mutation that usually occurs with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. L100V is a rare non-polymorphic mutation with low / intermediate resistance to EFV, NVP, and RPV.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,M230L": {
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,N348I": {
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,P225H": {
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V106A": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V106A,E138Q": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V106A,F227L": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V106A,Y181C": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V106A,Y181C,G190A": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V106I": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V106I,G190S": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V106I,V108I,G190A": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V106I,V108I,Y181C": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V106I,V108I,Y181C,G190S,H221Y": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V106I,V179D,Y181C,G190A": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V106I,V179D,Y188L": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V106I,V179E,Y188L": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V106I,V179F,Y181C,G190A": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT179F": "V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V106I,V179L,G190A,H221Y": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT179L": "V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V106I,V179L,Y181C,G190A,H221Y": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT179L": "V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V106I,Y181C": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V106I,Y181C,G190A": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V106I,Y181C,G190S": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V106I,Y181C,H221Y": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V106I,Y181C,Y188C": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V106I,Y181C,Y188L": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V106I,Y181V,G190A,F227L": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V106I,Y188L": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V106I,Y188L,H221Y": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V106M": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V106M,F227L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V106M,G190A": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V106M,G190A,F227L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V106M,V108I,H221Y,F227C": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227C": "F227C is a nonpolymorphic mutation selected in persons receiving DOR and rarely in persons receiving ETR and RPV. It usually occurs in combination with other DRMs and in this setting has consistently been associated with the highest possible levels of DOR resistance. It is also usually associated with intermediate or higher reductions in susceptibility to NVP, EFV, ETR, and RPV. ",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V106M,Y181C": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V106M,Y181C,F227L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V106M,Y181C,G190A": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V106M,Y188C": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V106M,Y188C,H221Y": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V106M,Y188L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V108I": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V108I,E138G,Y181C": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V108I,E138K,V179E": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V108I,E138Q,Y181C,G190A": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V108I,F227L": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V108I,G190A": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V108I,G190A,F227L": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V108I,G190A,H221Y,Y318F": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V108I,H221Y": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V108I,V179D,Y181C,G190A": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V108I,V179E": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V108I,V179E,H221Y": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V108I,V179E,Y181C": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V108I,V179E,Y181C,F227L": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V108I,V179E,Y181C,G190A": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V108I,V179E,Y181C,M230L": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V108I,V179F,Y181C,G190A": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179F": "V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V108I,V179T,Y181C,G190A": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179T": "V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V108I,Y181C": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V108I,Y181C,F227L": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V108I,Y181C,F227L,M230L": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V108I,Y181C,G190A": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V108I,Y181C,G190A,F227L": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V108I,Y181C,G190A,H221Y": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V108I,Y181C,G190A,H221Y,F227L": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V108I,Y181C,G190A,H221Y,K238T": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V108I,Y181C,G190A,H221Y,N348I": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V108I,Y181C,G190S": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V108I,Y181C,G190T,F227L": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190CTV": "G190C/T/V are rare non-polymorphic mutations that cause high-level resistance to NVP and EFV. Their effects on ETR, RPV, and DOR susceptibility are not known.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V108I,Y181C,H221Y": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V108I,Y181C,H221Y,F227L": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V108I,Y181C,H221Y,N348I": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V108I,Y181I": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V108I,Y181V,G190A,H221Y,F227L": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V179D": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V179D,G190A": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V179D,G190Q": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190EQ": "G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V179D,G190S": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V179D,Y181C,G190A": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V179D,Y181C,G190A,K238T": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V179D,Y181C,G190A,P225H": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V179E": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V179E,Y181C": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V179E,Y181C,G190A": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V179E,Y181C,H221Y": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V179E,Y181C,M230L": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V179E,Y181I": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V179E,Y188L": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V179E,Y188L,H221Y,F227L": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V179F,Y181C,G190A": {
    "RT179F": "V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V179L,G190A": {
    "RT179L": "V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V179L,Y181C": {
    "RT179L": "V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V179T,Y181C,G190A,P225H": {
    "RT179T": "V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,V179T,Y181C,G190S": {
    "RT179T": "V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,Y181C": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,Y181C,F227L": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,Y181C,G190A": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,Y181C,G190A,F227L": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,Y181C,G190A,H221Y": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,Y181C,G190A,H221Y,K238T": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,Y181C,G190A,K238T": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,Y181C,G190E": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190EQ": "G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,Y181C,G190S": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,Y181C,G190S,H221Y": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,Y181C,G190S,H221Y,N348I": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,Y181C,H221Y": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,Y181C,H221Y,Y318F": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,Y181C,K238T": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,Y181C,M230L": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,Y181C,Y188L": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,Y181C,Y318F": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,Y181F": {
    "RT181FSG": "Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,Y181G,G190A,H221Y": {
    "RT181FSG": "Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,Y181I": {
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,Y181S": {
    "RT181FSG": "Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,Y181V": {
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,Y181V,G190A": {
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,Y188C": {
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,Y188H": {
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,Y188L": {
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,Y188L,G190A": {
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,Y188L,G190A,H221Y": {
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,Y188L,G190S": {
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,Y188L,H221Y": {
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,Y188L,Y318F": {
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "A98G,Y318F": {
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied.",
    "RT98G": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
  },
  "E138A": {
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
  },
  "E138A,G190A": {
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "E138A,G190A,F227L": {
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "E138A,G190E": {
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190EQ": "G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known."
  },
  "E138A,G190E,H221Y": {
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190EQ": "G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "E138A,G190E,N348I": {
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190EQ": "G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "E138A,G190E,P225H": {
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190EQ": "G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "E138A,G190Q": {
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190EQ": "G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known."
  },
  "E138A,G190S": {
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "E138A,G190S,K238T": {
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "E138A,G190V": {
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190CTV": "G190C/T/V are rare non-polymorphic mutations that cause high-level resistance to NVP and EFV. Their effects on ETR, RPV, and DOR susceptibility are not known."
  },
  "E138A,H221Y": {
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "E138A,K238N": {
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "E138A,K238T": {
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "E138A,M230L": {
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "E138A,N348I": {
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "E138A,V179D": {
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "E138A,V179D,N348I": {
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "E138A,V179E": {
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "E138A,V179E,H221Y": {
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "E138A,V179E,Y181I,H221Y": {
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "E138A,V179F,Y188L": {
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT179F": "V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "E138A,V179L": {
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT179L": "V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert."
  },
  "E138A,Y181C": {
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "E138A,Y181C,G190A,H221Y": {
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "E138A,Y181C,G190A,N348I": {
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "E138A,Y181C,H221Y": {
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "E138A,Y181C,Y188L,G190A": {
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "E138A,Y181F": {
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181FSG": "Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V."
  },
  "E138A,Y181I": {
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized."
  },
  "E138A,Y181I,G190A": {
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "E138A,Y181I,H221Y": {
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "E138A,Y181S": {
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181FSG": "Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V."
  },
  "E138A,Y181V,G190E,N348I": {
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT190EQ": "G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "E138A,Y188C": {
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV."
  },
  "E138A,Y188H": {
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV."
  },
  "E138A,Y188L": {
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "E138A,Y188L,G190A": {
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "E138A,Y188L,H221Y": {
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "E138A,Y318F": {
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "E138G": {
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR."
  },
  "E138G,F227L,M230L": {
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "E138G,G190A": {
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "E138G,G190S": {
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "E138G,H221Y,F227L,M230L": {
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "E138G,H221Y,M230L,K238N": {
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "E138G,M230L": {
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "E138G,V179D": {
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "E138G,V179D,G190A": {
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "E138G,V179D,G190A,H221Y": {
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "E138G,V179D,Y181I,Y188L": {
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "E138G,V179E": {
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "E138G,V179E,G190S": {
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "E138G,V179E,Y181C,G190A": {
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "E138G,V179E,Y188L": {
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "E138G,V179E,Y188L,N348I": {
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "E138G,Y181C": {
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "E138G,Y181C,G190A": {
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "E138G,Y181C,H221Y": {
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "E138G,Y181I": {
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized."
  },
  "E138G,Y188L": {
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "E138K": {
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR."
  },
  "E138K,G190A": {
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "E138K,G190A,M230L": {
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "E138K,G190E": {
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT190EQ": "G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known."
  },
  "E138K,G190Q": {
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT190EQ": "G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known."
  },
  "E138K,M184I": {
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT184VI": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
  },
  "E138K,V179D": {
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "E138K,V179E": {
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "E138K,V179E,Y188C": {
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV."
  },
  "E138K,V179E,Y188L": {
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "E138K,Y181C": {
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "E138K,Y181C,G190A,H221Y": {
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "E138K,Y181C,M184I,M230L": {
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT184VI": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "E138K,Y188L": {
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "E138Q": {
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR."
  },
  "E138Q,G190A": {
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "E138Q,G190A,N348I": {
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "E138Q,G190E": {
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT190EQ": "G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known."
  },
  "E138Q,G190E,H221Y": {
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT190EQ": "G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "E138Q,V179D": {
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "E138Q,V179D,G190A": {
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "E138Q,V179E,G190S": {
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "E138Q,V179L": {
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT179L": "V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert."
  },
  "E138Q,Y181C": {
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "E138Q,Y181C,G190A": {
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "E138Q,Y181C,G190A,N348I": {
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "E138Q,Y188L": {
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "E138Q,Y188L,F227L": {
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "E138R": {
    "RT138R": "E138R is a rare non-polymorphic accessory mutation selected in vitro by RPV. It is associated with 2 to 3-fold reduced susceptibility to ETR and RPV."
  },
  "E138R,G190A": {
    "RT138R": "E138R is a rare non-polymorphic accessory mutation selected in vitro by RPV. It is associated with 2 to 3-fold reduced susceptibility to ETR and RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "E138R,G190E,H221Y": {
    "RT138R": "E138R is a rare non-polymorphic accessory mutation selected in vitro by RPV. It is associated with 2 to 3-fold reduced susceptibility to ETR and RPV.",
    "RT190EQ": "G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "F227C": {
    "RT227C": "F227C is a nonpolymorphic mutation selected in persons receiving DOR and rarely in persons receiving ETR and RPV. It usually occurs in combination with other DRMs and in this setting has consistently been associated with the highest possible levels of DOR resistance. It is also usually associated with intermediate or higher reductions in susceptibility to NVP, EFV, ETR, and RPV. "
  },
  "F227I": {
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "F227L": {
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "F227L,K238N": {
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "F227L,M230L": {
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "F227V": {
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "G190A": {
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "G190A,F227L": {
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "G190A,F227L,K238T": {
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "G190A,H221Y": {
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "G190A,H221Y,F227L": {
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "G190A,H221Y,M230L": {
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "G190A,K238N": {
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "G190A,K238T": {
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "G190A,M230L": {
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "G190A,N348I": {
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "G190A,P225H": {
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "G190A,Y318F": {
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "G190A,Y318F,N348I": {
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "G190C": {
    "RT190CTV": "G190C/T/V are rare non-polymorphic mutations that cause high-level resistance to NVP and EFV. Their effects on ETR, RPV, and DOR susceptibility are not known."
  },
  "G190C,H221Y": {
    "RT190CTV": "G190C/T/V are rare non-polymorphic mutations that cause high-level resistance to NVP and EFV. Their effects on ETR, RPV, and DOR susceptibility are not known.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "G190C,P225H": {
    "RT190CTV": "G190C/T/V are rare non-polymorphic mutations that cause high-level resistance to NVP and EFV. Their effects on ETR, RPV, and DOR susceptibility are not known.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "G190E": {
    "RT190EQ": "G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known."
  },
  "G190E,H221Y": {
    "RT190EQ": "G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "G190E,N348I": {
    "RT190EQ": "G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "G190E,P225H,M230I": {
    "RT190EQ": "G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT230I": "M230I is an extremely rare mutation selected by RPV. Its effects on NNRTI susceptibility have not been well studied. It also often occurs as a result of APOBEC-mediated G-to-A hypermutation resulting in viruses that are likely to be noninfectious."
  },
  "G190Q": {
    "RT190EQ": "G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known."
  },
  "G190Q,H221Y": {
    "RT190EQ": "G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "G190Q,N348I": {
    "RT190EQ": "G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "G190S": {
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "G190S,H221Y": {
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "G190S,K238N": {
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "G190S,K238T": {
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "G190S,K238T,N348I": {
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "G190S,M230L": {
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "G190S,N348I": {
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "G190S,P225H": {
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "G190T": {
    "RT190CTV": "G190C/T/V are rare non-polymorphic mutations that cause high-level resistance to NVP and EFV. Their effects on ETR, RPV, and DOR susceptibility are not known."
  },
  "G190T,H221Y": {
    "RT190CTV": "G190C/T/V are rare non-polymorphic mutations that cause high-level resistance to NVP and EFV. Their effects on ETR, RPV, and DOR susceptibility are not known.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "G190V": {
    "RT190CTV": "G190C/T/V are rare non-polymorphic mutations that cause high-level resistance to NVP and EFV. Their effects on ETR, RPV, and DOR susceptibility are not known."
  },
  "H221Y": {
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "H221Y,F227L": {
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "H221Y,K238N": {
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "H221Y,N348I": {
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "H221Y,Y318F": {
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "K101E": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
  },
  "K101E,E138A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
  },
  "K101E,E138A,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,E138A,G190A,F227L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101E,E138A,G190A,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,E138A,G190A,H221Y,F227L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101E,E138A,G190A,K238N": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K101E,E138A,G190A,K238T": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K101E,E138A,G190A,N348I": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K101E,E138A,G190C": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190CTV": "G190C/T/V are rare non-polymorphic mutations that cause high-level resistance to NVP and EFV. Their effects on ETR, RPV, and DOR susceptibility are not known."
  },
  "K101E,E138A,G190Q": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190EQ": "G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known."
  },
  "K101E,E138A,G190S": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101E,E138A,G190V": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190CTV": "G190C/T/V are rare non-polymorphic mutations that cause high-level resistance to NVP and EFV. Their effects on ETR, RPV, and DOR susceptibility are not known."
  },
  "K101E,E138A,K238T": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K101E,E138A,M184I,Y188L,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT184VI": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,E138A,V179D,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,E138A,V179E,Y188L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "K101E,E138A,V179F,Y181C,G190A,H221Y,P225H": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT179F": "V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K101E,E138A,Y181C": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K101E,E138A,Y181C,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,E138A,Y181C,G190A,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,E138A,Y181C,G190A,M230L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K101E,E138A,Y181C,G190S": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101E,E138A,Y181C,H221Y,M230L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K101E,E138A,Y181I": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized."
  },
  "K101E,E138A,Y181I,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,E138A,Y188C,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,E138A,Y188L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "K101E,E138A,Y188L,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,E138G": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR."
  },
  "K101E,E138G,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,E138G,G190S": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101E,E138G,V179D,Y181I,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,E138G,V179T,Y181C,G190S": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT179T": "V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101E,E138G,Y181C": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K101E,E138K": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR."
  },
  "K101E,E138K,G190E": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT190EQ": "G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known."
  },
  "K101E,E138K,G190S": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101E,E138K,V179E": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "K101E,E138K,Y181C": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K101E,E138K,Y181C,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,E138K,Y181C,G190S,H221Y,N348I": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K101E,E138K,Y181C,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,E138K,Y181I,G190S": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101E,E138K,Y188H,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,E138K,Y188L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "K101E,E138K,Y188L,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,E138K,Y188L,N348I": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K101E,E138Q": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR."
  },
  "K101E,E138Q,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,E138Q,G190Q": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT190EQ": "G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known."
  },
  "K101E,E138Q,G190S": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101E,E138Q,V179E,G190S": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101E,E138Q,V179L,Y181C,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT179L": "V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,E138Q,Y181C,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,E138Q,Y181C,G190S": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101E,E138Q,Y181C,M184I,G190A,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT184VI": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,E138R,G190E": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138R": "E138R is a rare non-polymorphic accessory mutation selected in vitro by RPV. It is associated with 2 to 3-fold reduced susceptibility to ETR and RPV.",
    "RT190EQ": "G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known."
  },
  "K101E,E138R,G190S": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138R": "E138R is a rare non-polymorphic accessory mutation selected in vitro by RPV. It is associated with 2 to 3-fold reduced susceptibility to ETR and RPV.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101E,F227L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101E,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,G190A,F227L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101E,G190A,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,G190A,K238T": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K101E,G190A,N348I": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K101E,G190A,P225H": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K101E,G190A,Y318F": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "K101E,G190C": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT190CTV": "G190C/T/V are rare non-polymorphic mutations that cause high-level resistance to NVP and EFV. Their effects on ETR, RPV, and DOR susceptibility are not known."
  },
  "K101E,G190S": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101E,G190S,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,G190S,N348I": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K101E,G190S,P225H": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K101E,G190S,Y318F": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "K101E,G190T": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT190CTV": "G190C/T/V are rare non-polymorphic mutations that cause high-level resistance to NVP and EFV. Their effects on ETR, RPV, and DOR susceptibility are not known."
  },
  "K101E,G190V": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT190CTV": "G190C/T/V are rare non-polymorphic mutations that cause high-level resistance to NVP and EFV. Their effects on ETR, RPV, and DOR susceptibility are not known."
  },
  "K101E,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,H221Y,P225H": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K101E,K103H,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103H": "K103H is a rare non-polymorphic mutation that causes high-level resistance to NVP and EFV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,K103H,V108I,G190A,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103H": "K103H is a rare non-polymorphic mutation that causes high-level resistance to NVP and EFV.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,K103N": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
  },
  "K101E,K103N,E138A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
  },
  "K101E,K103N,E138A,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,K103N,E138A,G190A,P225H": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K101E,K103N,E138A,G190S": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101E,K103N,E138A,K238T": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K101E,K103N,E138G": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR."
  },
  "K101E,K103N,E138K": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR."
  },
  "K101E,K103N,E138Q,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,K103N,E138Q,Y181C,G190A,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,K103N,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,K103N,G190A,F227L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101E,K103N,G190A,H221Y,K238N": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K101E,K103N,G190A,P225H": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K101E,K103N,G190S": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101E,K103N,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,K103N,K238T": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K101E,K103N,M184I": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT184VI": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
  },
  "K101E,K103N,M184I,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT184VI": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,K103N,M184I,Y188L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT184VI": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "K101E,K103N,M230L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K101E,K103N,N348I": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K101E,K103N,P225H": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K101E,K103N,P225H,K238T": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K101E,K103N,P225H,N348I": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K101E,K103N,V106A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance."
  },
  "K101E,K103N,V106A,E138A,G190A,F227L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101E,K103N,V106A,E138K,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,K103N,V106A,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,K103N,V106A,Y181C": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K101E,K103N,V106A,Y181C,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,K103N,V106A,Y181C,G190A,F227L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101E,K103N,V106I": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. "
  },
  "K101E,K103N,V106I,E138G,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,K103N,V106I,E138K": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR."
  },
  "K101E,K103N,V106I,E138K,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,K103N,V106I,V108I,Y181I": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized."
  },
  "K101E,K103N,V106I,V179E": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "K101E,K103N,V106I,Y188L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "K101E,K103N,V106M": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101E,K103N,V106M,E138A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
  },
  "K101E,K103N,V106M,E138A,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,K103N,V106M,E138A,Y181I,H221Y,M230L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K101E,K103N,V106M,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,K103N,V106M,N348I": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K101E,K103N,V106M,V108I": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
  },
  "K101E,K103N,V106M,Y181C,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,K103N,V108I": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
  },
  "K101E,K103N,V108I,E138A,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,K103N,V108I,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,K103N,V108I,G190A,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,K103N,V108I,G190A,N348I": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K101E,K103N,V108I,G190A,P225H": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K101E,K103N,V108I,P225H": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K101E,K103N,V108I,Y181C": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K101E,K103N,V108I,Y181C,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,K103N,V108I,Y181C,G190A,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,K103N,V108I,Y181C,K238T": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K101E,K103N,V108I,Y181S,G190S,N348I": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181FSG": "Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K101E,K103N,Y181C": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K101E,K103N,Y181C,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,K103N,Y181C,G190A,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,K103N,Y181C,G190S": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101E,K103N,Y181C,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,K103N,Y181C,M184I": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT184VI": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
  },
  "K101E,K103N,Y181C,M184I,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT184VI": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,K103N,Y181V,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,K103N,Y188C": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV."
  },
  "K101E,K103N,Y188H,G190S": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101E,K103N,Y188L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "K101E,K103N,Y188L,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,K103R,E138A,V179D,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,K103R,E138K,V179D": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "K101E,K103R,V179D,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,K103R,V179D,Y181C,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,K103S": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N."
  },
  "K101E,K103S,E138A,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,K103S,E138G,Y181C,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,K103S,E138Q,Y181C,G190A,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,K103S,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,K103S,G190S": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101E,K103S,V106I,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,K103T": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103T": "K103T is an extremely rare non-polymorphic mutation that appears to cause intermediate/high-level resistance to NVP. It has little if any effect on EFV susceptibility."
  },
  "K101E,M184I": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT184VI": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
  },
  "K101E,M184I,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT184VI": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,M184I,G190A,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT184VI": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,M184I,G190S": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT184VI": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101E,M184I,Y188C": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT184VI": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV."
  },
  "K101E,M184I,Y188L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT184VI": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "K101E,N348I": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K101E,V106A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance."
  },
  "K101E,V106A,E138A,F227L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101E,V106A,E138A,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,V106A,F227L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101E,V106A,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,V106A,G190A,F227L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101E,V106A,V108I,Y181C,G190A,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,V106A,V108I,Y181C,G190A,H221Y,F227L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101E,V106A,Y181C": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K101E,V106A,Y181C,G190A,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,V106I": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. "
  },
  "K101E,V106I,E138A,Y188L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "K101E,V106I,E138G,G190S": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101E,V106I,E138G,Y181C,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,V106I,E138K": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR."
  },
  "K101E,V106I,E138Q,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,V106I,E138Q,G190S": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101E,V106I,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,V106I,G190A,M230L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K101E,V106I,G190S": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101E,V106I,G190S,N348I": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K101E,V106I,G190T": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT190CTV": "G190C/T/V are rare non-polymorphic mutations that cause high-level resistance to NVP and EFV. Their effects on ETR, RPV, and DOR susceptibility are not known."
  },
  "K101E,V106I,G190V": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT190CTV": "G190C/T/V are rare non-polymorphic mutations that cause high-level resistance to NVP and EFV. Their effects on ETR, RPV, and DOR susceptibility are not known."
  },
  "K101E,V106I,M184I,Y188L,N348I": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT184VI": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K101E,V106I,V108I,G190A,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,V106I,V108I,G190S": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101E,V106I,V108I,M230L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K101E,V106I,V108I,Y181C": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K101E,V106I,V108I,Y181C,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,V106I,V108I,Y181C,G190S": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101E,V106I,V179D,Y188L,G190A,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,V106I,V179F,Y181C,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT179F": "V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,V106I,V179L,Y188L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT179L": "V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "K101E,V106I,Y181C": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K101E,V106I,Y181C,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,V106I,Y181C,G190A,H221Y,F227L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101E,V106I,Y181C,G190S": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101E,V106I,Y181C,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,V106I,Y181I,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,V106I,Y181V,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,V106I,Y188C": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV."
  },
  "K101E,V106I,Y188H,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,V106I,Y188L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "K101E,V106I,Y188L,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,V106I,Y188L,K238N": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K101E,V106M": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101E,V106M,E138A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
  },
  "K101E,V106M,E138A,F227L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101E,V106M,E138A,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,V106M,E138A,G190A,F227L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101E,V106M,E138A,Y181C,G190A,H221Y,F227L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101E,V106M,E138A,Y181V,G190A,H221Y,F227L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101E,V106M,E138G,G190A,F227L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101E,V106M,E138G,G190A,M230L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K101E,V106M,E138G,Y181C,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,V106M,E138Q,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,V106M,E138Q,Y181C,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,V106M,F227C": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT227C": "F227C is a nonpolymorphic mutation selected in persons receiving DOR and rarely in persons receiving ETR and RPV. It usually occurs in combination with other DRMs and in this setting has consistently been associated with the highest possible levels of DOR resistance. It is also usually associated with intermediate or higher reductions in susceptibility to NVP, EFV, ETR, and RPV. "
  },
  "K101E,V106M,F227I": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101E,V106M,F227L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101E,V106M,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,V106M,G190A,F227L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101E,V106M,G190A,N348I": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K101E,V106M,G190S": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101E,V106M,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,V106M,H221Y,F227L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101E,V106M,M184I": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT184VI": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
  },
  "K101E,V106M,M184I,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT184VI": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,V106M,V108I": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
  },
  "K101E,V106M,V108I,E138A,G190A,F227L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101E,V106M,V108I,F227L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101E,V106M,V108I,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,V106M,V179D": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "K101E,V106M,V179D,G190A,H221Y,F227L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101E,V106M,Y181C": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K101E,V106M,Y181C,F227L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101E,V106M,Y181C,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,V106M,Y181C,G190A,F227L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101E,V106M,Y181C,G190S": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101E,V106M,Y181C,M184I,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT184VI": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,V106M,Y181C,M184I,H221Y,F227L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT184VI": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101E,V106M,Y181V,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,V106M,Y181V,G190A,F227L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101E,V106M,Y188C": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV."
  },
  "K101E,V106M,Y188L,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,V108I": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
  },
  "K101E,V108I,E138A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
  },
  "K101E,V108I,E138A,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,V108I,E138A,H221Y,F227L,M230L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K101E,V108I,E138A,Y181C,G190A,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,V108I,E138A,Y181C,G190A,M230L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K101E,V108I,E138A,Y181I,G190A,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,V108I,E138G,Y181C,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,V108I,E138G,Y181C,G190A,P225H": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K101E,V108I,E138K": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR."
  },
  "K101E,V108I,E138K,Y181C,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,V108I,E138Q,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,V108I,E138Q,G190A,H221Y,F227L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101E,V108I,E138Q,Y181C,G190A,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,V108I,E138Q,Y181C,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,V108I,F227L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101E,V108I,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,V108I,G190A,F227L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101E,V108I,G190A,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,V108I,G190A,H221Y,M230L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K101E,V108I,G190A,N348I": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K101E,V108I,G190A,Y318F,N348I": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K101E,V108I,G190S": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101E,V108I,G190S,K238T": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K101E,V108I,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,V108I,V179D,Y181C,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,V108I,V179F,Y181C,G190A,H221Y,N348I": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179F": "V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K101E,V108I,Y181C": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K101E,V108I,Y181C,F227L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101E,V108I,Y181C,F227L,K238T": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K101E,V108I,Y181C,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,V108I,Y181C,G190A,F227L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101E,V108I,Y181C,G190A,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,V108I,Y181C,G190A,H221Y,F227L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101E,V108I,Y181C,G190A,H221Y,N348I": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K101E,V108I,Y181C,G190A,H221Y,P225H": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K101E,V108I,Y181C,G190A,K238N": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K101E,V108I,Y181C,G190A,N348I": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K101E,V108I,Y181C,G190A,P225H": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K101E,V108I,Y181C,G190A,Y318F": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "K101E,V108I,Y181C,G190S": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101E,V108I,Y181C,G190S,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,V108I,Y181C,G190S,K238T": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K101E,V108I,Y181C,G190S,N348I": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K101E,V108I,Y181C,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,V108I,Y181C,H221Y,M230L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K101E,V108I,Y181C,M184I": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT184VI": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
  },
  "K101E,V108I,Y181C,M184I,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT184VI": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,V108I,Y181C,M184I,G190A,H221Y,F227L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT184VI": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101E,V108I,Y181I,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,V108I,Y181V": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized."
  },
  "K101E,V108I,Y181V,G190A,N348I": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K101E,V108I,Y181V,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,V179D": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "K101E,V179D,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,V179D,Y181I": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized."
  },
  "K101E,V179D,Y188L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "K101E,V179E": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "K101E,V179E,G190A,P225H": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K101E,V179E,Y181C,M184I,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT184VI": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,V179E,Y188L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "K101E,V179F,Y181C": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT179F": "V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K101E,V179F,Y181C,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT179F": "V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,V179F,Y181C,G190A,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT179F": "V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,V179F,Y181C,G190S": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT179F": "V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101E,V179F,Y181C,G190S,K238T": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT179F": "V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K101E,V179F,Y181C,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT179F": "V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,V179T,Y181C": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT179T": "V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K101E,V179T,Y181C,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT179T": "V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,V179T,Y181C,G190A,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT179T": "V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,V179T,Y181C,G190S": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT179T": "V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101E,Y181C": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K101E,Y181C,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,Y181C,G190A,F227L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101E,Y181C,G190A,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,Y181C,G190A,H221Y,F227L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101E,Y181C,G190A,K238N": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K101E,Y181C,G190A,K238T": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K101E,Y181C,G190A,N348I": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K101E,Y181C,G190A,P225H": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K101E,Y181C,G190E": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190EQ": "G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known."
  },
  "K101E,Y181C,G190S": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101E,Y181C,G190S,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,Y181C,G190S,K238T": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K101E,Y181C,G190S,N348I": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K101E,Y181C,G190S,P225H": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K101E,Y181C,G190T": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190CTV": "G190C/T/V are rare non-polymorphic mutations that cause high-level resistance to NVP and EFV. Their effects on ETR, RPV, and DOR susceptibility are not known."
  },
  "K101E,Y181C,G190T,K238T": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190CTV": "G190C/T/V are rare non-polymorphic mutations that cause high-level resistance to NVP and EFV. Their effects on ETR, RPV, and DOR susceptibility are not known.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K101E,Y181C,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,Y181C,K238T": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K101E,Y181C,M184I": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT184VI": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
  },
  "K101E,Y181C,M184I,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT184VI": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,Y181C,M184I,G190A,M230L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT184VI": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K101E,Y181C,M184I,G190S": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT184VI": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101E,Y181C,M184I,G190S,N348I": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT184VI": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K101E,Y181C,M184I,G190S,P225H": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT184VI": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K101E,Y181C,M184I,M230L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT184VI": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K101E,Y181C,M184I,Y188L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT184VI": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "K101E,Y181C,M230L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K101E,Y181C,N348I": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K101E,Y181C,P225H": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K101E,Y181C,Y188H,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,Y181C,Y188L,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,Y181C,Y188L,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,Y181F": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181FSG": "Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V."
  },
  "K101E,Y181I": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized."
  },
  "K101E,Y181I,G190S": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101E,Y181I,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,Y181I,Y188L,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,Y181S,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181FSG": "Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,Y181S,G190A,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181FSG": "Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,Y181V": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized."
  },
  "K101E,Y181V,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,Y181V,G190A,H221Y": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101E,Y181V,G190S": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101E,Y181V,M184I": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT184VI": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
  },
  "K101E,Y188C": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV."
  },
  "K101E,Y188F,G190S": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT188F": "Y188F is a rare non-polymorphic NNRTI-associated mutation that is usually present as part of an electrophoretic mixture. It appears to represent a transitional mutation between Y and L.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101E,Y188H,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,Y188H,G190S,K238T": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K101E,Y188L": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "K101E,Y188L,G190A": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101E,Y188L,G190S": {
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101H": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known."
  },
  "K101H,E138A": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
  },
  "K101H,E138A,V179D": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "K101H,E138A,V179E,Y188L": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "K101H,E138A,Y181C,G190A": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101H,E138G,G190A": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101H,G190A": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101H,G190A,H221Y": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101H,G190A,K238T": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K101H,G190A,M230L": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K101H,G190A,N348I": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K101H,G190S": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101H,K103N": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
  },
  "K101H,K103N,G190A": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101H,K103N,G190S": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101H,K103N,V106M": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101H,K103N,V108I,Y181C,G190A": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101H,K103N,Y181C": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K101H,K103N,Y181C,G190A": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101H,K103N,Y181C,G190A,F227L": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101H,K103N,Y181C,G190A,H221Y": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101H,K103N,Y188L": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "K101H,K103S,G190A": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101H,P225H": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K101H,V106A": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance."
  },
  "K101H,V106A,Y181C": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K101H,V106I": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. "
  },
  "K101H,V106I,E138A,G190A": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101H,V106I,G190A": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101H,V106I,G190A,F227L": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101H,V106I,G190S": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101H,V106I,V108I,G190A,H221Y": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101H,V106I,V108I,Y181C": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K101H,V106I,V108I,Y181C,G190A,Y318F": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "K101H,V106I,Y181C,G190A": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101H,V106I,Y181C,G190A,H221Y,F227L": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101H,V106I,Y181C,G190S": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101H,V106I,Y188L": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "K101H,V106I,Y188L,G190A": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101H,V106M": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101H,V106M,E138A,H221Y,F227L": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101H,V106M,E138A,V179D,G190A": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101H,V106M,F227L": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101H,V106M,F227L,K238T": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K101H,V106M,G190A": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101H,V106M,G190A,F227L": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101H,V106M,P225H,M230L": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K101H,V106M,V179D,F227L": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101H,V106M,Y181C": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K101H,V106M,Y181C,G190A": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101H,V108I,E138K,Y181C,M184I,G190A,H221Y": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT184VI": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101H,V108I,V179E,Y181C,G190A": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101H,V108I,Y181C": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K101H,V108I,Y181C,G190A": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101H,V108I,Y181C,G190A,H221Y": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101H,V108I,Y181C,G190A,H221Y,F227L": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101H,V108I,Y181C,G190A,H221Y,N348I": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K101H,V108I,Y181C,G190A,P225H": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K101H,V108I,Y181C,H221Y": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101H,V108I,Y181C,H221Y,M230L": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K101H,V179D,G190S": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101H,V179T,Y181C,G190S,F227L": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT179T": "V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101H,Y181C": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K101H,Y181C,G190A": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101H,Y181C,G190A,H221Y": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101H,Y181C,G190A,K238T": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K101H,Y181C,G190A,N348I": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K101H,Y181C,G190A,Y318F": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "K101H,Y181C,G190S": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101H,Y181C,H221Y": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101H,Y181F,Y188L,H221Y": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT181FSG": "Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101H,Y181I": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized."
  },
  "K101H,Y181V": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized."
  },
  "K101H,Y188C,G190A": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101H,Y188L": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "K101H,Y188L,G190A": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101H,Y188L,H221Y": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101H,Y188L,K238T": {
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K101P": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility."
  },
  "K101P,E138G,V179L": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT179L": "V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert."
  },
  "K101P,E138Q,G190A": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101P,E138Q,Y188L,Y318F": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "K101P,G190A": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101P,G190A,H221Y": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101P,G190A,N348I": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K101P,G190A,P225H": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K101P,G190A,Y318F": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "K101P,G190S": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101P,H221Y": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101P,H221Y,K238T": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K101P,K103N": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
  },
  "K101P,K103N,E138A": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
  },
  "K101P,K103N,E138A,H221Y": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101P,K103N,E138A,N348I": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K101P,K103N,E138Q": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR."
  },
  "K101P,K103N,E138Q,G190A,H221Y": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101P,K103N,G190A": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101P,K103N,G190A,N348I": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K101P,K103N,G190S": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101P,K103N,H221Y": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101P,K103N,K238T": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K101P,K103N,N348I": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K101P,K103N,P225H": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K101P,K103N,V106A,V108I": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
  },
  "K101P,K103N,V106I": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. "
  },
  "K101P,K103N,V106M": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101P,K103N,V108I": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
  },
  "K101P,K103N,V108I,H221Y": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101P,K103N,V108I,V179L": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179L": "V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert."
  },
  "K101P,K103N,V179L": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179L": "V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert."
  },
  "K101P,K103N,Y181S": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181FSG": "Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V."
  },
  "K101P,K103N,Y188H": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV."
  },
  "K101P,K103N,Y318F": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "K101P,K103R,V179D": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "K101P,K103R,V179D,M230L,K238T": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K101P,K103S": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N."
  },
  "K101P,K103S,E138A": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
  },
  "K101P,K103S,E138G": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR."
  },
  "K101P,K103S,E138Q": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR."
  },
  "K101P,K103S,G190A": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101P,K103S,H221Y": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101P,K103S,N348I": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K101P,K103S,V106I": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. "
  },
  "K101P,K103S,V106M": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101P,K103S,V108I": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
  },
  "K101P,K103S,V108I,H221Y": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101P,K103T": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT103T": "K103T is an extremely rare non-polymorphic mutation that appears to cause intermediate/high-level resistance to NVP. It has little if any effect on EFV susceptibility."
  },
  "K101P,M230L": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K101P,M230L,K238N": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K101P,N348I": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K101P,V106A": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance."
  },
  "K101P,V106A,G190A": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101P,V106I": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. "
  },
  "K101P,V106I,G190A": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101P,V106I,G190A,H221Y": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101P,V106I,G190A,K238T": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K101P,V106I,Y188C": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV."
  },
  "K101P,V106I,Y188F,G190A": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT188F": "Y188F is a rare non-polymorphic NNRTI-associated mutation that is usually present as part of an electrophoretic mixture. It appears to represent a transitional mutation between Y and L.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101P,V106M": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101P,V106M,E138A,F227L": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101P,V106M,V108I,G190A,H221Y": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101P,V108I,G190A": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101P,V108I,G190A,P225H": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K101P,V108I,V179L": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179L": "V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert."
  },
  "K101P,V108I,V179L,Y181C,H221Y": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179L": "V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101P,V108I,Y181C": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K101P,V179D": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "K101P,V179L": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT179L": "V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert."
  },
  "K101P,V179L,G190A": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT179L": "V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101P,V179L,G190A,K238T": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT179L": "V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K101P,V179L,G190S": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT179L": "V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K101P,Y181C": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K101P,Y181C,G190A": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K101P,Y181C,G190A,H221Y": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101P,Y181C,H221Y": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101P,Y188F,H221Y": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT188F": "Y188F is a rare non-polymorphic NNRTI-associated mutation that is usually present as part of an electrophoretic mixture. It appears to represent a transitional mutation between Y and L.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K101P,Y188L": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "K101P,Y188L,F227L": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K101P,Y188L,H221Y": {
    "RT101P": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103H,V108I,Y181C,G190A": {
    "RT103H": "K103H is a rare non-polymorphic mutation that causes high-level resistance to NVP and EFV.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103H,V108I,Y181C,G190A,H221Y": {
    "RT103H": "K103H is a rare non-polymorphic mutation that causes high-level resistance to NVP and EFV.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103H,Y181C,G190A": {
    "RT103H": "K103H is a rare non-polymorphic mutation that causes high-level resistance to NVP and EFV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103H,Y181C,G190A,H221Y": {
    "RT103H": "K103H is a rare non-polymorphic mutation that causes high-level resistance to NVP and EFV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103H,Y181C,G190A,N348I": {
    "RT103H": "K103H is a rare non-polymorphic mutation that causes high-level resistance to NVP and EFV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
  },
  "K103N,E138A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
  },
  "K103N,E138A,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103N,E138A,G190S": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K103N,E138A,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,E138A,H221Y,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103N,E138A,H221Y,M230L,L234I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.",
    "RT234I": "L234I is a nonpolymorphic mutation selected in persons receiving NVP and EFV. It is also selected in vitro by ETR and DOR. In combination with V106A, it is associated with high-level DOR resistance. Its effect on susceptibility when it occurs alone has not been studied."
  },
  "K103N,E138A,K238N": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,E138A,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,E138A,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103N,E138A,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,E138A,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103N,E138A,P225H,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103N,E138A,P225H,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,E138A,P225H,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103N,E138A,V179D": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "K103N,E138A,V179E": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "K103N,E138A,V179E,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,E138A,V179E,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103N,E138A,V179L,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT179L": "V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,E138A,Y181C": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K103N,E138A,Y181C,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103N,E138A,Y181C,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103N,E138A,Y181C,G190A,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,E138A,Y181C,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,E138A,Y181I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized."
  },
  "K103N,E138A,Y181S": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181FSG": "Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V."
  },
  "K103N,E138A,Y188F": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT188F": "Y188F is a rare non-polymorphic NNRTI-associated mutation that is usually present as part of an electrophoretic mixture. It appears to represent a transitional mutation between Y and L."
  },
  "K103N,E138A,Y188H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV."
  },
  "K103N,E138A,Y188L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "K103N,E138A,Y318F": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "K103N,E138G": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR."
  },
  "K103N,E138G,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103N,E138G,G190A,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,E138G,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,E138G,H221Y,P225H,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103N,E138G,K238N": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,E138G,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,E138G,K238T,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,E138G,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103N,E138G,M230L,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,E138G,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,E138G,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103N,E138G,P225H,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,E138G,P225H,L234I,Y318F": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT234I": "L234I is a nonpolymorphic mutation selected in persons receiving NVP and EFV. It is also selected in vitro by ETR and DOR. In combination with V106A, it is associated with high-level DOR resistance. Its effect on susceptibility when it occurs alone has not been studied.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "K103N,E138G,P225H,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103N,E138G,V179E": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "K103N,E138G,V179E,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103N,E138G,V179E,Y188H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV."
  },
  "K103N,E138G,Y181C": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K103N,E138G,Y181C,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,E138G,Y181C,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103N,E138G,Y181C,Y188C": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV."
  },
  "K103N,E138G,Y188C": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV."
  },
  "K103N,E138G,Y188H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV."
  },
  "K103N,E138G,Y188H,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,E138G,Y188L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "K103N,E138G,Y188L,G190S": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K103N,E138G,Y318F": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "K103N,E138K": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR."
  },
  "K103N,E138K,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103N,E138K,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103N,E138K,Y181C,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103N,E138Q": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR."
  },
  "K103N,E138Q,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103N,E138Q,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103N,E138Q,G190A,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,E138Q,G190S": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K103N,E138Q,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,E138Q,K238N": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,E138Q,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,E138Q,K238T,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,E138Q,K238T,Y318F,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,E138Q,L234I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT234I": "L234I is a nonpolymorphic mutation selected in persons receiving NVP and EFV. It is also selected in vitro by ETR and DOR. In combination with V106A, it is associated with high-level DOR resistance. Its effect on susceptibility when it occurs alone has not been studied."
  },
  "K103N,E138Q,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103N,E138Q,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,E138Q,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103N,E138Q,P225H,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,E138Q,V179E": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "K103N,E138Q,V179E,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,E138Q,V179E,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103N,E138Q,Y181C": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K103N,E138Q,Y181C,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103N,E138Q,Y181C,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,E138Q,Y181C,H221Y,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103N,E138Q,Y181F": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181FSG": "Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V."
  },
  "K103N,E138Q,Y188H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV."
  },
  "K103N,E138Q,Y188L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "K103N,E138Q,Y188L,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,E138Q,Y318F": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "K103N,E138Q,Y318F,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,E138R,V179E,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138R": "E138R is a rare non-polymorphic accessory mutation selected in vitro by RPV. It is associated with 2 to 3-fold reduced susceptibility to ETR and RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103N,E138R,V179E,P225H,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138R": "E138R is a rare non-polymorphic accessory mutation selected in vitro by RPV. It is associated with 2 to 3-fold reduced susceptibility to ETR and RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,E138R,Y188L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138R": "E138R is a rare non-polymorphic accessory mutation selected in vitro by RPV. It is associated with 2 to 3-fold reduced susceptibility to ETR and RPV.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "K103N,F227C": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT227C": "F227C is a nonpolymorphic mutation selected in persons receiving DOR and rarely in persons receiving ETR and RPV. It usually occurs in combination with other DRMs and in this setting has consistently been associated with the highest possible levels of DOR resistance. It is also usually associated with intermediate or higher reductions in susceptibility to NVP, EFV, ETR, and RPV. "
  },
  "K103N,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103N,F227L,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103N,F227L,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103N,G190A,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,G190A,H221Y,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,G190A,K238N": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,G190A,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,G190A,K238T,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,G190A,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103N,G190A,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,G190A,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103N,G190E": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT190EQ": "G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known."
  },
  "K103N,G190E,P225H,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT190EQ": "G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,G190S": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K103N,G190S,K238N": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,G190S,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103N,G190T,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT190CTV": "G190C/T/V are rare non-polymorphic mutations that cause high-level resistance to NVP and EFV. Their effects on ETR, RPV, and DOR susceptibility are not known.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,H221Y,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103N,H221Y,F227L,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,H221Y,F227L,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103N,H221Y,F227L,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,H221Y,K238N": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,H221Y,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,H221Y,L234I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT234I": "L234I is a nonpolymorphic mutation selected in persons receiving NVP and EFV. It is also selected in vitro by ETR and DOR. In combination with V106A, it is associated with high-level DOR resistance. Its effect on susceptibility when it occurs alone has not been studied."
  },
  "K103N,H221Y,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103N,H221Y,M230L,L234I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.",
    "RT234I": "L234I is a nonpolymorphic mutation selected in persons receiving NVP and EFV. It is also selected in vitro by ETR and DOR. In combination with V106A, it is associated with high-level DOR resistance. Its effect on susceptibility when it occurs alone has not been studied."
  },
  "K103N,H221Y,M230L,L234I,Y318F": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.",
    "RT234I": "L234I is a nonpolymorphic mutation selected in persons receiving NVP and EFV. It is also selected in vitro by ETR and DOR. In combination with V106A, it is associated with high-level DOR resistance. Its effect on susceptibility when it occurs alone has not been studied.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "K103N,H221Y,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,H221Y,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103N,H221Y,P225H,F227C,L234I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT227C": "F227C is a nonpolymorphic mutation selected in persons receiving DOR and rarely in persons receiving ETR and RPV. It usually occurs in combination with other DRMs and in this setting has consistently been associated with the highest possible levels of DOR resistance. It is also usually associated with intermediate or higher reductions in susceptibility to NVP, EFV, ETR, and RPV. ",
    "RT234I": "L234I is a nonpolymorphic mutation selected in persons receiving NVP and EFV. It is also selected in vitro by ETR and DOR. In combination with V106A, it is associated with high-level DOR resistance. Its effect on susceptibility when it occurs alone has not been studied."
  },
  "K103N,H221Y,P225H,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,H221Y,P225H,L234I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT234I": "L234I is a nonpolymorphic mutation selected in persons receiving NVP and EFV. It is also selected in vitro by ETR and DOR. In combination with V106A, it is associated with high-level DOR resistance. Its effect on susceptibility when it occurs alone has not been studied."
  },
  "K103N,H221Y,P225H,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103N,H221Y,P225H,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,K238N": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,K238N,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,K238T,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,K238T,Y318F": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "K103N,L234I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT234I": "L234I is a nonpolymorphic mutation selected in persons receiving NVP and EFV. It is also selected in vitro by ETR and DOR. In combination with V106A, it is associated with high-level DOR resistance. Its effect on susceptibility when it occurs alone has not been studied."
  },
  "K103N,L234I,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT234I": "L234I is a nonpolymorphic mutation selected in persons receiving NVP and EFV. It is also selected in vitro by ETR and DOR. In combination with V106A, it is associated with high-level DOR resistance. Its effect on susceptibility when it occurs alone has not been studied.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,L234I,Y318F": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT234I": "L234I is a nonpolymorphic mutation selected in persons receiving NVP and EFV. It is also selected in vitro by ETR and DOR. In combination with V106A, it is associated with high-level DOR resistance. Its effect on susceptibility when it occurs alone has not been studied.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "K103N,M230I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT230I": "M230I is an extremely rare mutation selected by RPV. Its effects on NNRTI susceptibility have not been well studied. It also often occurs as a result of APOBEC-mediated G-to-A hypermutation resulting in viruses that are likely to be noninfectious."
  },
  "K103N,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103N,M230L,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,M230L,L234I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.",
    "RT234I": "L234I is a nonpolymorphic mutation selected in persons receiving NVP and EFV. It is also selected in vitro by ETR and DOR. In combination with V106A, it is associated with high-level DOR resistance. Its effect on susceptibility when it occurs alone has not been studied."
  },
  "K103N,M230L,L234I,Y318F": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.",
    "RT234I": "L234I is a nonpolymorphic mutation selected in persons receiving NVP and EFV. It is also selected in vitro by ETR and DOR. In combination with V106A, it is associated with high-level DOR resistance. Its effect on susceptibility when it occurs alone has not been studied.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "K103N,M230L,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103N,P225H,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103N,P225H,F227V": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103N,P225H,K238N": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,P225H,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,P225H,K238T,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,P225H,K238T,Y318F,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,P225H,L234I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT234I": "L234I is a nonpolymorphic mutation selected in persons receiving NVP and EFV. It is also selected in vitro by ETR and DOR. In combination with V106A, it is associated with high-level DOR resistance. Its effect on susceptibility when it occurs alone has not been studied."
  },
  "K103N,P225H,L234I,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT234I": "L234I is a nonpolymorphic mutation selected in persons receiving NVP and EFV. It is also selected in vitro by ETR and DOR. In combination with V106A, it is associated with high-level DOR resistance. Its effect on susceptibility when it occurs alone has not been studied.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,P225H,M230I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT230I": "M230I is an extremely rare mutation selected by RPV. Its effects on NNRTI susceptibility have not been well studied. It also often occurs as a result of APOBEC-mediated G-to-A hypermutation resulting in viruses that are likely to be noninfectious."
  },
  "K103N,P225H,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103N,P225H,M230L,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,P225H,M230L,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,P225H,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,P225H,Y318F": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "K103N,V106A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance."
  },
  "K103N,V106A,E138A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
  },
  "K103N,V106A,E138A,V179D": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "K103N,V106A,E138G,Y181C": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K103N,V106A,E138K": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR."
  },
  "K103N,V106A,E138Q,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,V106A,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103N,V106A,F227L,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,V106A,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103N,V106A,G190A,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103N,V106A,G190A,H221Y,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103N,V106A,G190A,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,V106A,G190S,K238N": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,V106A,H221Y,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103N,V106A,H221Y,F227L,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,V106A,H221Y,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103N,V106A,H221Y,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103N,V106A,K238N": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,V106A,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,V106A,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103N,V106A,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,V106A,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103N,V106A,P225H,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103N,V106A,V108I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
  },
  "K103N,V106A,V108I,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103N,V106A,V108I,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103N,V106A,V108I,G190A,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103N,V106A,V108I,H221Y,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103N,V106A,V108I,K238N": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,V106A,V108I,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,V106A,V108I,P225H,F227L,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,V106A,V108I,P225H,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,V106A,V108I,Y181C": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K103N,V106A,V108I,Y181C,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103N,V106A,V108I,Y181C,G190A,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103N,V106A,Y181C": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K103N,V106A,Y181C,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103N,V106A,Y181C,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103N,V106A,Y181C,G190A,H221Y,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103N,V106A,Y181C,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,V106A,Y181C,H221Y,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103N,V106A,Y181C,Y188C": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV."
  },
  "K103N,V106A,Y181C,Y188C,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103N,V106A,Y188C": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV."
  },
  "K103N,V106A,Y188H,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103N,V106I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. "
  },
  "K103N,V106I,E138A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
  },
  "K103N,V106I,E138Q,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103N,V106I,E138Q,Y181C,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,V106I,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103N,V106I,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103N,V106I,G190A,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,V106I,G190A,H221Y,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103N,V106I,G190A,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,V106I,G190A,Y318F": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "K103N,V106I,G190E": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT190EQ": "G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known."
  },
  "K103N,V106I,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,V106I,H221Y,F227L,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103N,V106I,H221Y,F227L,M230L,L234I,Y318F": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.",
    "RT234I": "L234I is a nonpolymorphic mutation selected in persons receiving NVP and EFV. It is also selected in vitro by ETR and DOR. In combination with V106A, it is associated with high-level DOR resistance. Its effect on susceptibility when it occurs alone has not been studied.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "K103N,V106I,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103N,V106I,M230L,L234I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.",
    "RT234I": "L234I is a nonpolymorphic mutation selected in persons receiving NVP and EFV. It is also selected in vitro by ETR and DOR. In combination with V106A, it is associated with high-level DOR resistance. Its effect on susceptibility when it occurs alone has not been studied."
  },
  "K103N,V106I,M230L,L234I,Y318F,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.",
    "RT234I": "L234I is a nonpolymorphic mutation selected in persons receiving NVP and EFV. It is also selected in vitro by ETR and DOR. In combination with V106A, it is associated with high-level DOR resistance. Its effect on susceptibility when it occurs alone has not been studied.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,V106I,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,V106I,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103N,V106I,V108I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
  },
  "K103N,V106I,V108I,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,V106I,V108I,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103N,V106I,V108I,Y181C,G190A,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,V106I,V108I,Y181C,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,V106I,V108I,Y181C,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103N,V106I,V108I,Y181C,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103N,V106I,V179D": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "K103N,V106I,V179D,Y188F,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188F": "Y188F is a rare non-polymorphic NNRTI-associated mutation that is usually present as part of an electrophoretic mixture. It appears to represent a transitional mutation between Y and L.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103N,V106I,V179D,Y188L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "K103N,V106I,V179E,Y181C": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K103N,V106I,V179F,Y181C,G190A,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT179F": "V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,V106I,V179L,Y181C,H221Y,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT179L": "V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103N,V106I,V179L,Y181C,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT179L": "V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,V106I,Y181C": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K103N,V106I,Y181C,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103N,V106I,Y181C,G190A,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103N,V106I,Y181C,G190A,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,V106I,Y181C,G190A,H221Y,Y318F": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "K103N,V106I,Y181C,G190S,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,V106I,Y181C,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,V106I,Y188C,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103N,V106I,Y188C,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,V106I,Y188F,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT188F": "Y188F is a rare non-polymorphic NNRTI-associated mutation that is usually present as part of an electrophoretic mixture. It appears to represent a transitional mutation between Y and L.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103N,V106I,Y188H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV."
  },
  "K103N,V106I,Y188L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "K103N,V106I,Y188L,G190A,M230I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT230I": "M230I is an extremely rare mutation selected by RPV. Its effects on NNRTI susceptibility have not been well studied. It also often occurs as a result of APOBEC-mediated G-to-A hypermutation resulting in viruses that are likely to be noninfectious."
  },
  "K103N,V106I,Y188L,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,V106I,Y318F": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "K103N,V106M": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K103N,V106M,E138A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
  },
  "K103N,V106M,E138A,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103N,V106M,E138A,Y188L,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103N,V106M,E138G": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR."
  },
  "K103N,V106M,E138K,V179D,Y188C": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV."
  },
  "K103N,V106M,E138Q": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR."
  },
  "K103N,V106M,E138Q,V179D": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "K103N,V106M,E138Q,Y188H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV."
  },
  "K103N,V106M,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103N,V106M,F227L,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103N,V106M,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103N,V106M,G190A,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103N,V106M,G190S": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K103N,V106M,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,V106M,H221Y,F227I,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103N,V106M,H221Y,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103N,V106M,H221Y,M230L,L234I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.",
    "RT234I": "L234I is a nonpolymorphic mutation selected in persons receiving NVP and EFV. It is also selected in vitro by ETR and DOR. In combination with V106A, it is associated with high-level DOR resistance. Its effect on susceptibility when it occurs alone has not been studied."
  },
  "K103N,V106M,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,V106M,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103N,V106M,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,V106M,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103N,V106M,P225H,Y318F": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "K103N,V106M,V108I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
  },
  "K103N,V106M,V108I,E138A,V179E": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "K103N,V106M,V108I,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103N,V106M,V108I,G190A,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103N,V106M,V108I,H221Y,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,V106M,V108I,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103N,V106M,V108I,V179D": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "K103N,V106M,V108I,Y181V": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized."
  },
  "K103N,V106M,V179D": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "K103N,V106M,V179D,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103N,V106M,V179D,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103N,V106M,V179D,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103N,V106M,V179D,Y188C,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103N,V106M,V179D,Y188L,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,V106M,V179E": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "K103N,V106M,Y181C": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K103N,V106M,Y181C,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103N,V106M,Y181C,G190A,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103N,V106M,Y181C,Y188C,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103N,V106M,Y188C": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV."
  },
  "K103N,V106M,Y188F": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT188F": "Y188F is a rare non-polymorphic NNRTI-associated mutation that is usually present as part of an electrophoretic mixture. It appears to represent a transitional mutation between Y and L."
  },
  "K103N,V106M,Y188F,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT188F": "Y188F is a rare non-polymorphic NNRTI-associated mutation that is usually present as part of an electrophoretic mixture. It appears to represent a transitional mutation between Y and L.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103N,V106M,Y188H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV."
  },
  "K103N,V106M,Y188L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "K103N,V106M,Y188L,G190A,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,V106M,Y318F": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "K103N,V108I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
  },
  "K103N,V108I,E138A,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,V108I,E138A,H221Y,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,V108I,E138A,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103N,V108I,E138A,P225H,K238N": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,V108I,E138A,V179E": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "K103N,V108I,E138A,Y181C,H221Y,P225H,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103N,V108I,E138G": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR."
  },
  "K103N,V108I,E138G,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,V108I,E138G,L234I,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT234I": "L234I is a nonpolymorphic mutation selected in persons receiving NVP and EFV. It is also selected in vitro by ETR and DOR. In combination with V106A, it is associated with high-level DOR resistance. Its effect on susceptibility when it occurs alone has not been studied.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,V108I,E138G,P225H,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,V108I,E138G,Y181C,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,V108I,E138K": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR."
  },
  "K103N,V108I,E138K,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103N,V108I,E138K,Y181C": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K103N,V108I,E138Q": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR."
  },
  "K103N,V108I,E138Q,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,V108I,E138Q,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,V108I,E138Q,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103N,V108I,E138Q,Y181C": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K103N,V108I,E138Q,Y181C,G190A,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,V108I,E138Q,Y181C,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,V108I,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103N,V108I,F227L,K238N": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,V108I,F227L,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,V108I,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103N,V108I,G190A,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,V108I,G190A,H221Y,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103N,V108I,G190A,H221Y,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,V108I,G190A,H221Y,P225H,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103N,V108I,G190A,H221Y,P225H,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,V108I,G190A,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,V108I,G190A,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,V108I,G190A,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103N,V108I,G190E": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190EQ": "G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known."
  },
  "K103N,V108I,G190S,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,V108I,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,V108I,H221Y,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103N,V108I,H221Y,F227L,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,V108I,H221Y,F227L,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103N,V108I,H221Y,K238N": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,V108I,H221Y,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,V108I,H221Y,L234I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT234I": "L234I is a nonpolymorphic mutation selected in persons receiving NVP and EFV. It is also selected in vitro by ETR and DOR. In combination with V106A, it is associated with high-level DOR resistance. Its effect on susceptibility when it occurs alone has not been studied."
  },
  "K103N,V108I,H221Y,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103N,V108I,H221Y,M230L,K238N": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,V108I,H221Y,M230L,L234I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.",
    "RT234I": "L234I is a nonpolymorphic mutation selected in persons receiving NVP and EFV. It is also selected in vitro by ETR and DOR. In combination with V106A, it is associated with high-level DOR resistance. Its effect on susceptibility when it occurs alone has not been studied."
  },
  "K103N,V108I,H221Y,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,V108I,H221Y,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103N,V108I,H221Y,P225H,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103N,V108I,H221Y,P225H,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103N,V108I,H221Y,Y318F": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "K103N,V108I,H221Y,Y318F,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,V108I,K238N": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,V108I,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,V108I,K238T,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,V108I,L234I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT234I": "L234I is a nonpolymorphic mutation selected in persons receiving NVP and EFV. It is also selected in vitro by ETR and DOR. In combination with V106A, it is associated with high-level DOR resistance. Its effect on susceptibility when it occurs alone has not been studied."
  },
  "K103N,V108I,L234I,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT234I": "L234I is a nonpolymorphic mutation selected in persons receiving NVP and EFV. It is also selected in vitro by ETR and DOR. In combination with V106A, it is associated with high-level DOR resistance. Its effect on susceptibility when it occurs alone has not been studied.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,V108I,L234I,Y318F": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT234I": "L234I is a nonpolymorphic mutation selected in persons receiving NVP and EFV. It is also selected in vitro by ETR and DOR. In combination with V106A, it is associated with high-level DOR resistance. Its effect on susceptibility when it occurs alone has not been studied.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "K103N,V108I,M230I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT230I": "M230I is an extremely rare mutation selected by RPV. Its effects on NNRTI susceptibility have not been well studied. It also often occurs as a result of APOBEC-mediated G-to-A hypermutation resulting in viruses that are likely to be noninfectious."
  },
  "K103N,V108I,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103N,V108I,M230L,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,V108I,M230L,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,V108I,M230L,Y318F": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "K103N,V108I,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,V108I,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103N,V108I,P225H,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103N,V108I,P225H,K238N": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,V108I,P225H,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,V108I,P225H,L234I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT234I": "L234I is a nonpolymorphic mutation selected in persons receiving NVP and EFV. It is also selected in vitro by ETR and DOR. In combination with V106A, it is associated with high-level DOR resistance. Its effect on susceptibility when it occurs alone has not been studied."
  },
  "K103N,V108I,P225H,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103N,V108I,P225H,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,V108I,V179E": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "K103N,V108I,V179E,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103N,V108I,V179E,G190S": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K103N,V108I,V179E,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,V108I,V179E,H221Y,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103N,V108I,V179E,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103N,V108I,V179E,P225H,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,V108I,V179E,Y181C": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K103N,V108I,V179E,Y181C,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,V108I,V179F,Y181C": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179F": "V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K103N,V108I,V179F,Y181C,G190A,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179F": "V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,V108I,V179F,Y181C,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179F": "V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,V108I,V179L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179L": "V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert."
  },
  "K103N,V108I,V179L,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179L": "V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,V108I,V179L,Y181C,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179L": "V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103N,V108I,Y181C": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K103N,V108I,Y181C,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103N,V108I,Y181C,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103N,V108I,Y181C,G190A,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103N,V108I,Y181C,G190A,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,V108I,Y181C,G190A,H221Y,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,V108I,Y181C,G190A,H221Y,M230I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT230I": "M230I is an extremely rare mutation selected by RPV. Its effects on NNRTI susceptibility have not been well studied. It also often occurs as a result of APOBEC-mediated G-to-A hypermutation resulting in viruses that are likely to be noninfectious."
  },
  "K103N,V108I,Y181C,G190A,H221Y,P225H,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,V108I,Y181C,G190A,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103N,V108I,Y181C,G190S,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,V108I,Y181C,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,V108I,Y181C,H221Y,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103N,V108I,Y181C,H221Y,K238N": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,V108I,Y181C,H221Y,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,V108I,Y181C,H221Y,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,V108I,Y181C,H221Y,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103N,V108I,Y181C,H221Y,P225H,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,V108I,Y181C,K238N": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,V108I,Y181C,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,V108I,Y181C,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103N,V108I,Y181C,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,V108I,Y181C,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103N,V108I,Y181C,P225H,F227L,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,V108I,Y181C,P225H,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,V108I,Y181C,Y188H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV."
  },
  "K103N,V108I,Y181C,Y318F": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "K103N,V108I,Y181G,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181FSG": "Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,V108I,Y181G,H221Y,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181FSG": "Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,V108I,Y181V": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized."
  },
  "K103N,V108I,Y181V,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103N,V108I,Y181V,G190A,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,V108I,Y181V,G190A,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,V108I,Y181V,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,V108I,Y188H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV."
  },
  "K103N,V108I,Y188H,H221Y,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103N,V108I,Y188L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "K103N,V108I,Y318F": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "K103N,V108I,Y318F,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,V179D": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "K103N,V179D,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103N,V179D,G190A,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103N,V179D,Y181C": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K103N,V179D,Y181C,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103N,V179D,Y188L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "K103N,V179E": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "K103N,V179E,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103N,V179E,G190A,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,V179E,G190A,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,V179E,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,V179E,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,V179E,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103N,V179E,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,V179E,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103N,V179E,Y181C": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K103N,V179E,Y181C,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103N,V179E,Y181C,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,V179E,Y181C,P225H,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103N,V179E,Y181C,Y188H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV."
  },
  "K103N,V179E,Y188L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "K103N,V179F,Y181C": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179F": "V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K103N,V179F,Y181C,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179F": "V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103N,V179F,Y181C,G190A,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179F": "V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,V179F,Y181C,G190A,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179F": "V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,V179F,Y181C,G190A,Y318F": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179F": "V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "K103N,V179F,Y181C,G190S,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179F": "V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,V179F,Y181C,G190S,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179F": "V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,V179F,Y181C,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179F": "V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,V179F,Y181C,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179F": "V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,V179F,Y188H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179F": "V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV."
  },
  "K103N,V179F,Y188L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179F": "V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "K103N,V179L,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179L": "V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,V179L,Y181C": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179L": "V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K103N,V179L,Y181C,G190A,H221Y,K238N": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179L": "V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,V179L,Y181I,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179L": "V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103N,V179L,Y188L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179L": "V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "K103N,V179T,Y181C": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179T": "V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K103N,V179T,Y181C,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179T": "V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103N,V179T,Y181C,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179T": "V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,V179T,Y181C,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179T": "V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,V179T,Y181C,Y188L,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179T": "V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,Y181C": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K103N,Y181C,F227C,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT227C": "F227C is a nonpolymorphic mutation selected in persons receiving DOR and rarely in persons receiving ETR and RPV. It usually occurs in combination with other DRMs and in this setting has consistently been associated with the highest possible levels of DOR resistance. It is also usually associated with intermediate or higher reductions in susceptibility to NVP, EFV, ETR, and RPV. ",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103N,Y181C,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103N,Y181C,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103N,Y181C,G190A,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103N,Y181C,G190A,F227L,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,Y181C,G190A,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,Y181C,G190A,H221Y,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103N,Y181C,G190A,H221Y,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,Y181C,G190A,H221Y,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,Y181C,G190A,H221Y,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103N,Y181C,G190A,K238N": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,Y181C,G190A,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,Y181C,G190A,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103N,Y181C,G190A,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,Y181C,G190A,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103N,Y181C,G190A,P225H,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,Y181C,G190A,Y318F": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "K103N,Y181C,G190S": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K103N,Y181C,G190S,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,Y181C,G190T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190CTV": "G190C/T/V are rare non-polymorphic mutations that cause high-level resistance to NVP and EFV. Their effects on ETR, RPV, and DOR susceptibility are not known."
  },
  "K103N,Y181C,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,Y181C,H221Y,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103N,Y181C,H221Y,K238N": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,Y181C,H221Y,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,Y181C,H221Y,L234I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT234I": "L234I is a nonpolymorphic mutation selected in persons receiving NVP and EFV. It is also selected in vitro by ETR and DOR. In combination with V106A, it is associated with high-level DOR resistance. Its effect on susceptibility when it occurs alone has not been studied."
  },
  "K103N,Y181C,H221Y,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103N,Y181C,H221Y,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,Y181C,H221Y,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103N,Y181C,H221Y,P225H,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,Y181C,K238N": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,Y181C,K238N,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,Y181C,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,Y181C,L234I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT234I": "L234I is a nonpolymorphic mutation selected in persons receiving NVP and EFV. It is also selected in vitro by ETR and DOR. In combination with V106A, it is associated with high-level DOR resistance. Its effect on susceptibility when it occurs alone has not been studied."
  },
  "K103N,Y181C,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103N,Y181C,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,Y181C,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103N,Y181C,P225H,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103N,Y181C,Y188C": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV."
  },
  "K103N,Y181C,Y188C,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103N,Y181C,Y188C,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,Y181C,Y188F": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188F": "Y188F is a rare non-polymorphic NNRTI-associated mutation that is usually present as part of an electrophoretic mixture. It appears to represent a transitional mutation between Y and L."
  },
  "K103N,Y181C,Y188H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV."
  },
  "K103N,Y181C,Y188H,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,Y181C,Y188L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "K103N,Y181C,Y188L,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,Y181F,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181FSG": "Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,Y181G,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181FSG": "Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,Y181I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized."
  },
  "K103N,Y181I,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103N,Y181I,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,Y181S": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181FSG": "Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V."
  },
  "K103N,Y181S,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181FSG": "Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103N,Y181V": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized."
  },
  "K103N,Y181V,G190A,K238N": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,Y181V,G190A,Y318F": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "K103N,Y181V,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,Y181V,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,Y181V,Y188L,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,Y188C": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV."
  },
  "K103N,Y188C,F227L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103N,Y188C,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103N,Y188C,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,Y188C,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103N,Y188F": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188F": "Y188F is a rare non-polymorphic NNRTI-associated mutation that is usually present as part of an electrophoretic mixture. It appears to represent a transitional mutation between Y and L."
  },
  "K103N,Y188F,G190S": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188F": "Y188F is a rare non-polymorphic NNRTI-associated mutation that is usually present as part of an electrophoretic mixture. It appears to represent a transitional mutation between Y and L.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K103N,Y188F,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188F": "Y188F is a rare non-polymorphic NNRTI-associated mutation that is usually present as part of an electrophoretic mixture. It appears to represent a transitional mutation between Y and L.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,Y188F,H221Y,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188F": "Y188F is a rare non-polymorphic NNRTI-associated mutation that is usually present as part of an electrophoretic mixture. It appears to represent a transitional mutation between Y and L.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103N,Y188F,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188F": "Y188F is a rare non-polymorphic NNRTI-associated mutation that is usually present as part of an electrophoretic mixture. It appears to represent a transitional mutation between Y and L.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,Y188F,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188F": "Y188F is a rare non-polymorphic NNRTI-associated mutation that is usually present as part of an electrophoretic mixture. It appears to represent a transitional mutation between Y and L.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103N,Y188F,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188F": "Y188F is a rare non-polymorphic NNRTI-associated mutation that is usually present as part of an electrophoretic mixture. It appears to represent a transitional mutation between Y and L.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103N,Y188H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV."
  },
  "K103N,Y188H,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103N,Y188H,G190A,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,Y188H,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,Y188H,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,Y188H,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103N,Y188H,P225H,K238N": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,Y188L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "K103N,Y188L,G190A": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103N,Y188L,G190A,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,Y188L,G190A,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,Y188L,G190E": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190EQ": "G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known."
  },
  "K103N,Y188L,G190S": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K103N,Y188L,H221Y": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103N,Y188L,H221Y,M230L,L234I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.",
    "RT234I": "L234I is a nonpolymorphic mutation selected in persons receiving NVP and EFV. It is also selected in vitro by ETR and DOR. In combination with V106A, it is associated with high-level DOR resistance. Its effect on susceptibility when it occurs alone has not been studied."
  },
  "K103N,Y188L,K238N": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,Y188L,K238T": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103N,Y188L,M230L": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103N,Y188L,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103N,Y188L,P225H": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103N,Y188L,P225H,L234I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT234I": "L234I is a nonpolymorphic mutation selected in persons receiving NVP and EFV. It is also selected in vitro by ETR and DOR. In combination with V106A, it is associated with high-level DOR resistance. Its effect on susceptibility when it occurs alone has not been studied."
  },
  "K103N,Y318F": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "K103N,Y318F,N348I": {
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103R,E138A,V179D": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "K103R,E138A,V179D,H221Y": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103R,E138A,V179D,Y181C,H221Y": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103R,E138A,V179D,Y318F": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "K103R,E138G,V179D,Y181I,Y188L": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "K103R,E138K,V179D": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "K103R,E138K,V179D,Y181C": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K103R,E138Q,V179D": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "K103R,E138Q,V179D,G190A": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103R,V106A,V179D": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "K103R,V106A,V179D,F227L": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103R,V106A,V179D,G190A,P225H": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103R,V106A,V179D,P225H": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103R,V106A,V179D,Y181C,G190A": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103R,V106A,V179D,Y181C,G190A,H221Y,F227L": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103R,V106I,E138K,V179D": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "K103R,V106I,V108I,V179D": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "K103R,V106I,V108I,V179D,G190A,H221Y": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103R,V106I,V108I,V179D,Y181C": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K103R,V106I,V108I,V179D,Y181C,H221Y,F227L": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103R,V106I,V179D": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "K103R,V106I,V179D,G190A": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103R,V106I,V179D,Y181C": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K103R,V106I,V179D,Y181C,G190A": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103R,V106I,V179D,Y181C,G190A,K238T": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103R,V106I,V179D,Y188L": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "K103R,V106I,V179D,Y188L,H221Y": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103R,V106M,E138A,V179D": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "K103R,V106M,E138A,V179D,F227L": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103R,V106M,E138A,V179D,G190A": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103R,V106M,E138A,V179D,M230L": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103R,V106M,E138G,V179D": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "K103R,V106M,V179D": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "K103R,V106M,V179D,F227L": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103R,V106M,V179D,G190A": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103R,V106M,V179D,H221Y,F227C": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227C": "F227C is a nonpolymorphic mutation selected in persons receiving DOR and rarely in persons receiving ETR and RPV. It usually occurs in combination with other DRMs and in this setting has consistently been associated with the highest possible levels of DOR resistance. It is also usually associated with intermediate or higher reductions in susceptibility to NVP, EFV, ETR, and RPV. "
  },
  "K103R,V106M,V179D,M230L": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103R,V106M,V179D,Y181C": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K103R,V106M,V179D,Y188C,G190E": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV.",
    "RT190EQ": "G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known."
  },
  "K103R,V106M,V179D,Y188H": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV."
  },
  "K103R,V108I,V179D": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "K103R,V108I,V179D,G190A": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103R,V108I,V179D,G190S": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K103R,V108I,V179D,H221Y,P225H": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103R,V108I,V179D,L234I": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT234I": "L234I is a nonpolymorphic mutation selected in persons receiving NVP and EFV. It is also selected in vitro by ETR and DOR. In combination with V106A, it is associated with high-level DOR resistance. Its effect on susceptibility when it occurs alone has not been studied."
  },
  "K103R,V108I,V179D,M230L,K238N": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103R,V108I,V179D,Y181C": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K103R,V108I,V179D,Y181C,G190A": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103R,V108I,V179D,Y181C,H221Y,F227L": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103R,V179D": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "K103R,V179D,G190A": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103R,V179D,G190A,H221Y,L234I": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT234I": "L234I is a nonpolymorphic mutation selected in persons receiving NVP and EFV. It is also selected in vitro by ETR and DOR. In combination with V106A, it is associated with high-level DOR resistance. Its effect on susceptibility when it occurs alone has not been studied."
  },
  "K103R,V179D,G190A,K238T": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103R,V179D,G190S": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K103R,V179D,H221Y,M230L": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103R,V179D,K238T": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103R,V179D,M230L": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103R,V179D,M230L,K238N": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103R,V179D,P225H": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103R,V179D,Y181C": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K103R,V179D,Y181C,G190A": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103R,V179D,Y181C,G190A,H221Y": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103R,V179D,Y181C,H221Y": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103R,V179D,Y181C,H221Y,M230L": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103R,V179D,Y181C,H221Y,Y318F": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "K103R,V179D,Y181C,Y188L": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "K103R,V179D,Y181I": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized."
  },
  "K103R,V179D,Y181S": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181FSG": "Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V."
  },
  "K103R,V179D,Y181V,Y188L": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "K103R,V179D,Y188C,G190A,M230L": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103R,V179D,Y188H": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV."
  },
  "K103R,V179D,Y188L": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "K103R,V179D,Y188L,F227L": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103R,V179D,Y188L,G190A": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103R,V179D,Y188L,H221Y": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103R,V179D,Y188L,N348I": {
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103S": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N."
  },
  "K103S,E138A": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
  },
  "K103S,E138A,G190A": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103S,E138G,G190A,K238T": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103S,E138K": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR."
  },
  "K103S,E138Q": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR."
  },
  "K103S,E138Q,G190S": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K103S,E138Q,K238T": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103S,E138Q,Y181C,F227L": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103S,E138Q,Y181C,G190A": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103S,G190A": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103S,G190A,H221Y": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103S,G190A,K238T": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103S,G190A,N348I": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103S,G190A,P225H": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103S,G190A,P225H,K238T": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103S,G190A,Y318F": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "K103S,G190S": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K103S,G190S,H221Y": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103S,G190S,K238T,N348I": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103S,H221Y": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103S,H221Y,P225H": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103S,K238N": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103S,K238T": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103S,N348I": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103S,P225H": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103S,V106A": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance."
  },
  "K103S,V106A,G190A,H221Y,F227L": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103S,V106A,G190A,N348I": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103S,V106A,G190A,P225H": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103S,V106A,H221Y": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103S,V106A,N348I": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103S,V106A,P225H": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103S,V106I": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. "
  },
  "K103S,V106I,E138G,Y181V": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized."
  },
  "K103S,V106I,G190A": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103S,V106I,G190A,K238T": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103S,V106I,G190A,N348I": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103S,V106I,V108I,Y181C,G190A": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103S,V106I,V179E,G190A": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103S,V106I,Y181C": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K103S,V106I,Y181C,G190A,H221Y": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103S,V106M": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K103S,V106M,E138A": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
  },
  "K103S,V106M,E138A,H221Y": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103S,V106M,E138G": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR."
  },
  "K103S,V106M,E138G,G190A": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103S,V106M,E138K,G190A": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103S,V106M,F227L": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103S,V106M,G190A,F227L": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103S,V106M,H221Y": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103S,V106M,M230L": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103S,V106M,V108I": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
  },
  "K103S,V106M,V108I,F227C,M230L": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT227C": "F227C is a nonpolymorphic mutation selected in persons receiving DOR and rarely in persons receiving ETR and RPV. It usually occurs in combination with other DRMs and in this setting has consistently been associated with the highest possible levels of DOR resistance. It is also usually associated with intermediate or higher reductions in susceptibility to NVP, EFV, ETR, and RPV. ",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103S,V106M,Y181C": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K103S,V108I": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
  },
  "K103S,V108I,E138K,Y181C,G190A": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103S,V108I,G190A": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103S,V108I,G190A,H221Y": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103S,V108I,G190A,N348I": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103S,V108I,H221Y": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103S,V108I,H221Y,K238N": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103S,V108I,Y181C": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K103S,V108I,Y181C,G190A": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103S,V108I,Y181C,H221Y": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103S,V179D": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "K103S,V179D,G190A": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103S,V179D,H221Y": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103S,V179D,Y181C,G190A": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103S,V179D,Y181C,G190A,H221Y": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103S,V179D,Y188C,G190A": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103S,V179D,Y188H": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV."
  },
  "K103S,V179E,G190A": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103S,V179E,Y181C,G190A,P225H,M230L": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103S,V179E,Y181I,G190A": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103S,V179F,Y181C": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT179F": "V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K103S,V179L,Y181C,H221Y": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT179L": "V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103S,Y181C": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K103S,Y181C,G190A": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103S,Y181C,G190A,H221Y": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103S,Y181C,H221Y": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103S,Y181C,H221Y,N348I": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K103S,Y181C,Y188L": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "K103S,Y181V,H221Y": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103S,Y188H": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV."
  },
  "K103S,Y188H,G190A": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103S,Y188L": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "K103S,Y188L,G190A": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103S,Y318F": {
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "K103T": {
    "RT103T": "K103T is an extremely rare non-polymorphic mutation that appears to cause intermediate/high-level resistance to NVP. It has little if any effect on EFV susceptibility."
  },
  "K103T,E138A": {
    "RT103T": "K103T is an extremely rare non-polymorphic mutation that appears to cause intermediate/high-level resistance to NVP. It has little if any effect on EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
  },
  "K103T,E138Q,Y181C": {
    "RT103T": "K103T is an extremely rare non-polymorphic mutation that appears to cause intermediate/high-level resistance to NVP. It has little if any effect on EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K103T,G190A": {
    "RT103T": "K103T is an extremely rare non-polymorphic mutation that appears to cause intermediate/high-level resistance to NVP. It has little if any effect on EFV susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103T,H221Y,M230L": {
    "RT103T": "K103T is an extremely rare non-polymorphic mutation that appears to cause intermediate/high-level resistance to NVP. It has little if any effect on EFV susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103T,K238N": {
    "RT103T": "K103T is an extremely rare non-polymorphic mutation that appears to cause intermediate/high-level resistance to NVP. It has little if any effect on EFV susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103T,M230L,K238T": {
    "RT103T": "K103T is an extremely rare non-polymorphic mutation that appears to cause intermediate/high-level resistance to NVP. It has little if any effect on EFV susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K103T,P225H": {
    "RT103T": "K103T is an extremely rare non-polymorphic mutation that appears to cause intermediate/high-level resistance to NVP. It has little if any effect on EFV susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "K103T,V106A": {
    "RT103T": "K103T is an extremely rare non-polymorphic mutation that appears to cause intermediate/high-level resistance to NVP. It has little if any effect on EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance."
  },
  "K103T,V106A,F227L": {
    "RT103T": "K103T is an extremely rare non-polymorphic mutation that appears to cause intermediate/high-level resistance to NVP. It has little if any effect on EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "K103T,V106A,Y181C": {
    "RT103T": "K103T is an extremely rare non-polymorphic mutation that appears to cause intermediate/high-level resistance to NVP. It has little if any effect on EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K103T,V106A,Y188L": {
    "RT103T": "K103T is an extremely rare non-polymorphic mutation that appears to cause intermediate/high-level resistance to NVP. It has little if any effect on EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "K103T,V106I": {
    "RT103T": "K103T is an extremely rare non-polymorphic mutation that appears to cause intermediate/high-level resistance to NVP. It has little if any effect on EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. "
  },
  "K103T,V106I,M230L": {
    "RT103T": "K103T is an extremely rare non-polymorphic mutation that appears to cause intermediate/high-level resistance to NVP. It has little if any effect on EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "K103T,V106I,Y181C": {
    "RT103T": "K103T is an extremely rare non-polymorphic mutation that appears to cause intermediate/high-level resistance to NVP. It has little if any effect on EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K103T,V106I,Y188H": {
    "RT103T": "K103T is an extremely rare non-polymorphic mutation that appears to cause intermediate/high-level resistance to NVP. It has little if any effect on EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV."
  },
  "K103T,V106M": {
    "RT103T": "K103T is an extremely rare non-polymorphic mutation that appears to cause intermediate/high-level resistance to NVP. It has little if any effect on EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "K103T,V106M,G190A": {
    "RT103T": "K103T is an extremely rare non-polymorphic mutation that appears to cause intermediate/high-level resistance to NVP. It has little if any effect on EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103T,V108I": {
    "RT103T": "K103T is an extremely rare non-polymorphic mutation that appears to cause intermediate/high-level resistance to NVP. It has little if any effect on EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
  },
  "K103T,V108I,H221Y": {
    "RT103T": "K103T is an extremely rare non-polymorphic mutation that appears to cause intermediate/high-level resistance to NVP. It has little if any effect on EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K103T,V108I,Y181C": {
    "RT103T": "K103T is an extremely rare non-polymorphic mutation that appears to cause intermediate/high-level resistance to NVP. It has little if any effect on EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K103T,V179D": {
    "RT103T": "K103T is an extremely rare non-polymorphic mutation that appears to cause intermediate/high-level resistance to NVP. It has little if any effect on EFV susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "K103T,Y181C": {
    "RT103T": "K103T is an extremely rare non-polymorphic mutation that appears to cause intermediate/high-level resistance to NVP. It has little if any effect on EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "K103T,Y181C,G190A": {
    "RT103T": "K103T is an extremely rare non-polymorphic mutation that appears to cause intermediate/high-level resistance to NVP. It has little if any effect on EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "K103T,Y181C,H221Y": {
    "RT103T": "K103T is an extremely rare non-polymorphic mutation that appears to cause intermediate/high-level resistance to NVP. It has little if any effect on EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "K238N": {
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "K238N,N348I": {
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "K238T": {
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "L100I": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N."
  },
  "L100I,E138A,G190E": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190EQ": "G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known."
  },
  "L100I,E138A,Y188L": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "L100I,E138K,H221Y": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "L100I,G190S,K238T": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "L100I,H221Y,M230L": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "L100I,K101E": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
  },
  "L100I,K101E,E138A,G190A,H221Y": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "L100I,K101E,E138A,Y188H,G190A,H221Y": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "L100I,K101E,G190A": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "L100I,K101E,G190S": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "L100I,K101E,K103N": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
  },
  "L100I,K101E,K103N,E138A": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
  },
  "L100I,K101E,K103N,G190S": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "L100I,K101E,K103N,V106I,E138A": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
  },
  "L100I,K101E,K103N,V106M": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "L100I,K101E,K103N,V108I,Y181C": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "L100I,K101E,K103S,V106M": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "L100I,K101E,K103T,E138A": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103T": "K103T is an extremely rare non-polymorphic mutation that appears to cause intermediate/high-level resistance to NVP. It has little if any effect on EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
  },
  "L100I,K101E,M230L": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "L100I,K101E,P225H": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "L100I,K101E,V106A,G190A,F227L": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "L100I,K101E,V106M,E138A,G190A,H221Y": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "L100I,K101E,V108I,E138A": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
  },
  "L100I,K101E,V108I,G190A": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "L100I,K101E,V179D,Y181I": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized."
  },
  "L100I,K101E,V179D,Y181I,G190A": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "L100I,K101E,Y181C,G190S": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "L100I,K101H,G190A": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT101H": "K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "L100I,K103N": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
  },
  "L100I,K103N,E138A": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
  },
  "L100I,K103N,E138A,H221Y": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "L100I,K103N,E138A,P225H": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "L100I,K103N,E138A,Y181C,G190A,H221Y": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "L100I,K103N,E138A,Y181I": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized."
  },
  "L100I,K103N,E138G": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR."
  },
  "L100I,K103N,E138G,H221Y": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "L100I,K103N,E138G,M230L": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "L100I,K103N,E138G,Y181I": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized."
  },
  "L100I,K103N,E138K": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR."
  },
  "L100I,K103N,E138K,N348I": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "L100I,K103N,E138Q": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR."
  },
  "L100I,K103N,E138Q,H221Y": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "L100I,K103N,E138Q,K238T": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "L100I,K103N,E138Q,P225H": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "L100I,K103N,E138Q,P225H,K238T": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "L100I,K103N,E138Q,Y181I": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized."
  },
  "L100I,K103N,E138R": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT138R": "E138R is a rare non-polymorphic accessory mutation selected in vitro by RPV. It is associated with 2 to 3-fold reduced susceptibility to ETR and RPV."
  },
  "L100I,K103N,F227L": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "L100I,K103N,F227L,K238T": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "L100I,K103N,G190A": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "L100I,K103N,G190A,H221Y": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "L100I,K103N,G190S,H221Y": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "L100I,K103N,H221Y": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "L100I,K103N,H221Y,K238N": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "L100I,K103N,H221Y,N348I": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "L100I,K103N,H221Y,P225H": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "L100I,K103N,K238N": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "L100I,K103N,K238T": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "L100I,K103N,M230L": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "L100I,K103N,M230L,N348I": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "L100I,K103N,N348I": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "L100I,K103N,P225H": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "L100I,K103N,P225H,K238T": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "L100I,K103N,P225H,M230L": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "L100I,K103N,P225H,N348I": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "L100I,K103N,V106A": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance."
  },
  "L100I,K103N,V106A,H221Y,F227L": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "L100I,K103N,V106I": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. "
  },
  "L100I,K103N,V106I,E138A": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
  },
  "L100I,K103N,V106I,G190A,H221Y": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "L100I,K103N,V106I,N348I": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "L100I,K103N,V106M": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "L100I,K103N,V106M,G190A,H221Y": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "L100I,K103N,V106M,H221Y": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "L100I,K103N,V106M,V179E,Y188C": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV."
  },
  "L100I,K103N,V106M,Y181C": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "L100I,K103N,V106M,Y188L,G190A": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "L100I,K103N,V108I": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
  },
  "L100I,K103N,V108I,E138A": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
  },
  "L100I,K103N,V108I,E138Q,K238N": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "L100I,K103N,V108I,G190E": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190EQ": "G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known."
  },
  "L100I,K103N,V108I,H221Y": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "L100I,K103N,V108I,H221Y,N348I": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "L100I,K103N,V108I,H221Y,P225H": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "L100I,K103N,V108I,K238T": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "L100I,K103N,V108I,L234I": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT234I": "L234I is a nonpolymorphic mutation selected in persons receiving NVP and EFV. It is also selected in vitro by ETR and DOR. In combination with V106A, it is associated with high-level DOR resistance. Its effect on susceptibility when it occurs alone has not been studied."
  },
  "L100I,K103N,V108I,P225H": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "L100I,K103N,V108I,P225H,N348I": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "L100I,K103N,V108I,V179E,H221Y": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "L100I,K103N,V108I,V179E,Y181C,G190A": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "L100I,K103N,V108I,V179L,Y181I": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179L": "V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized."
  },
  "L100I,K103N,V108I,Y181C": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "L100I,K103N,V108I,Y181C,G190A": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "L100I,K103N,V108I,Y181C,G190A,H221Y": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "L100I,K103N,V108I,Y181C,H221Y": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "L100I,K103N,V108I,Y181C,N348I": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "L100I,K103N,V179D,Y181I": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized."
  },
  "L100I,K103N,V179D,Y181I,H221Y,K238N": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "L100I,K103N,V179E": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "L100I,K103N,V179E,G190A": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "L100I,K103N,V179E,Y181C": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "L100I,K103N,V179F,Y181C": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179F": "V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "L100I,K103N,V179L,P225H,L234I": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT179L": "V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT234I": "L234I is a nonpolymorphic mutation selected in persons receiving NVP and EFV. It is also selected in vitro by ETR and DOR. In combination with V106A, it is associated with high-level DOR resistance. Its effect on susceptibility when it occurs alone has not been studied."
  },
  "L100I,K103N,Y181C": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "L100I,K103N,Y181C,G190A": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "L100I,K103N,Y181C,H221Y": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "L100I,K103N,Y181C,H221Y,P225H": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "L100I,K103N,Y181C,Y188L": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "L100I,K103N,Y181F": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181FSG": "Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V."
  },
  "L100I,K103N,Y181I": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized."
  },
  "L100I,K103N,Y181I,G190A,H221Y": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "L100I,K103N,Y181I,H221Y": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "L100I,K103N,Y181V": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized."
  },
  "L100I,K103N,Y188C": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV."
  },
  "L100I,K103N,Y188C,H221Y": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "L100I,K103N,Y188H": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV."
  },
  "L100I,K103N,Y188H,G190E": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV.",
    "RT190EQ": "G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known."
  },
  "L100I,K103N,Y188H,H221Y": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "L100I,K103N,Y188H,P225H": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "L100I,K103N,Y188L": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "L100I,K103N,Y188L,H221Y": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "L100I,K103N,Y318F": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "L100I,K103N,Y318F,N348I": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "L100I,K103R,E138K,V179D,H221Y": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "L100I,K103R,V106M,V179D,G190A": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "L100I,K103R,V108I,V179D,Y181C,H221Y,F227L": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "L100I,K103R,V179D": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "L100I,K103R,V179D,G190A": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "L100I,K103R,V179D,M230L": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "L100I,K103R,V179D,P225H": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "L100I,K103R,V179D,Y181I": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized."
  },
  "L100I,K103R,V179D,Y188L": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "L100I,K103S": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N."
  },
  "L100I,K103S,E138Q": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR."
  },
  "L100I,K103S,G190A": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "L100I,K103S,H221Y": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "L100I,K103S,V179D": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "L100I,K103S,V179D,Y181I,N348I": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "L100I,K103S,Y181C": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "L100I,K103S,Y318F": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "L100I,K103T": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT103T": "K103T is an extremely rare non-polymorphic mutation that appears to cause intermediate/high-level resistance to NVP. It has little if any effect on EFV susceptibility."
  },
  "L100I,M230L": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "L100I,N348I": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "L100I,V106A,G190A,F227L": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "L100I,V106I,Y188H": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV."
  },
  "L100I,V106I,Y188L": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "L100I,V106M,E138K,Y188F": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT188F": "Y188F is a rare non-polymorphic NNRTI-associated mutation that is usually present as part of an electrophoretic mixture. It appears to represent a transitional mutation between Y and L."
  },
  "L100I,V108I,Y181C,H221Y": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "L100I,V179D": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "L100I,V179D,G190A": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "L100I,V179D,N348I": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "L100I,V179D,Y181I": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized."
  },
  "L100I,V179D,Y181I,G190A": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "L100I,V179D,Y188L": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "L100I,V179E,Y188L": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "L100I,Y181C": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "L100I,Y181I,G190A": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "L100I,Y188C": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV."
  },
  "L100I,Y188F": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT188F": "Y188F is a rare non-polymorphic NNRTI-associated mutation that is usually present as part of an electrophoretic mixture. It appears to represent a transitional mutation between Y and L."
  },
  "L100I,Y188L": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "L100I,Y188L,G190A": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "L100I,Y188L,N348I": {
    "RT100I": "L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "L100V": {
    "RT100V": "L100I is a non-polymorphic mutation that usually occurs with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. L100V is a rare non-polymorphic mutation with low / intermediate resistance to EFV, NVP, and RPV."
  },
  "L100V,E138A": {
    "RT100V": "L100I is a non-polymorphic mutation that usually occurs with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. L100V is a rare non-polymorphic mutation with low / intermediate resistance to EFV, NVP, and RPV.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
  },
  "L100V,H221Y": {
    "RT100V": "L100I is a non-polymorphic mutation that usually occurs with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. L100V is a rare non-polymorphic mutation with low / intermediate resistance to EFV, NVP, and RPV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "L100V,K101E,G190S": {
    "RT100V": "L100I is a non-polymorphic mutation that usually occurs with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. L100V is a rare non-polymorphic mutation with low / intermediate resistance to EFV, NVP, and RPV.",
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "L100V,K101E,K103N": {
    "RT100V": "L100I is a non-polymorphic mutation that usually occurs with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. L100V is a rare non-polymorphic mutation with low / intermediate resistance to EFV, NVP, and RPV.",
    "RT101E": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
  },
  "L100V,K103N": {
    "RT100V": "L100I is a non-polymorphic mutation that usually occurs with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. L100V is a rare non-polymorphic mutation with low / intermediate resistance to EFV, NVP, and RPV.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
  },
  "L100V,K103N,G190A": {
    "RT100V": "L100I is a non-polymorphic mutation that usually occurs with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. L100V is a rare non-polymorphic mutation with low / intermediate resistance to EFV, NVP, and RPV.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "L100V,K103N,P225H": {
    "RT100V": "L100I is a non-polymorphic mutation that usually occurs with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. L100V is a rare non-polymorphic mutation with low / intermediate resistance to EFV, NVP, and RPV.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "L100V,K103N,V106A,F227L": {
    "RT100V": "L100I is a non-polymorphic mutation that usually occurs with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. L100V is a rare non-polymorphic mutation with low / intermediate resistance to EFV, NVP, and RPV.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "L100V,K103N,V106I,Y188L": {
    "RT100V": "L100I is a non-polymorphic mutation that usually occurs with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. L100V is a rare non-polymorphic mutation with low / intermediate resistance to EFV, NVP, and RPV.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "L100V,K103N,V106M": {
    "RT100V": "L100I is a non-polymorphic mutation that usually occurs with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. L100V is a rare non-polymorphic mutation with low / intermediate resistance to EFV, NVP, and RPV.",
    "RT103N": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "L100V,K103R,V106M,V179D": {
    "RT100V": "L100I is a non-polymorphic mutation that usually occurs with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. L100V is a rare non-polymorphic mutation with low / intermediate resistance to EFV, NVP, and RPV.",
    "RT103R": "K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "L100V,K103S,Y181C,H221Y": {
    "RT100V": "L100I is a non-polymorphic mutation that usually occurs with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. L100V is a rare non-polymorphic mutation with low / intermediate resistance to EFV, NVP, and RPV.",
    "RT103S": "K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "L100V,V108I,Y181C,G190A,H221Y": {
    "RT100V": "L100I is a non-polymorphic mutation that usually occurs with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. L100V is a rare non-polymorphic mutation with low / intermediate resistance to EFV, NVP, and RPV.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "L100V,V108I,Y181I,H221Y": {
    "RT100V": "L100I is a non-polymorphic mutation that usually occurs with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. L100V is a rare non-polymorphic mutation with low / intermediate resistance to EFV, NVP, and RPV.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "L100V,V179D": {
    "RT100V": "L100I is a non-polymorphic mutation that usually occurs with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. L100V is a rare non-polymorphic mutation with low / intermediate resistance to EFV, NVP, and RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "L100V,Y188H,G190A": {
    "RT100V": "L100I is a non-polymorphic mutation that usually occurs with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. L100V is a rare non-polymorphic mutation with low / intermediate resistance to EFV, NVP, and RPV.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "L234I": {
    "RT234I": "L234I is a nonpolymorphic mutation selected in persons receiving NVP and EFV. It is also selected in vitro by ETR and DOR. In combination with V106A, it is associated with high-level DOR resistance. Its effect on susceptibility when it occurs alone has not been studied."
  },
  "M230I": {
    "RT230I": "M230I is an extremely rare mutation selected by RPV. Its effects on NNRTI susceptibility have not been well studied. It also often occurs as a result of APOBEC-mediated G-to-A hypermutation resulting in viruses that are likely to be noninfectious."
  },
  "M230L": {
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "M230L,K238T": {
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "M230L,L234I": {
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.",
    "RT234I": "L234I is a nonpolymorphic mutation selected in persons receiving NVP and EFV. It is also selected in vitro by ETR and DOR. In combination with V106A, it is associated with high-level DOR resistance. Its effect on susceptibility when it occurs alone has not been studied."
  },
  "M230L,N348I": {
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "M230L,Y318F": {
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "N348I": {
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "P225H": {
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "P225H,K238T": {
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "V106A": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance."
  },
  "V106A,E138A": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
  },
  "V106A,E138A,F227L": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106A,E138A,G190A": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V106A,E138A,G190A,F227L": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106A,E138A,G190A,H221Y,F227L": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106A,E138A,H221Y,F227L": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106A,E138G,F227L": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106A,E138G,G190A,H221Y,F227L": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106A,E138G,V179D,G190A,H221Y": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V106A,E138K": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR."
  },
  "V106A,E138K,F227L": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106A,E138Q,H221Y": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V106A,F227L": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106A,F227L,N348I": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "V106A,F227V": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106A,G190A": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V106A,G190A,F227L": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106A,G190A,H221Y,F227L": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106A,G190A,K238N": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "V106A,G190A,P225H": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "V106A,G190E": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT190EQ": "G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known."
  },
  "V106A,G190S": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "V106A,G190S,H221Y": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V106A,G190S,H221Y,F227L": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106A,G190V": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT190CTV": "G190C/T/V are rare non-polymorphic mutations that cause high-level resistance to NVP and EFV. Their effects on ETR, RPV, and DOR susceptibility are not known."
  },
  "V106A,H221Y": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V106A,H221Y,F227L": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106A,H221Y,P225H": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "V106A,K238T": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "V106A,M230L": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "V106A,N348I": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "V106A,P225H": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "V106A,P225H,F227L": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106A,P225H,F227L,K238T": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "V106A,V108I,F227L": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106A,V108I,F227L,M230L": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "V106A,V108I,G190A": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V106A,V108I,G190A,F227L": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106A,V108I,Y181C,G190A": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V106A,V108I,Y181C,H221Y": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V106A,V179D,G190A": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V106A,V179D,G190A,F227L": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106A,V179D,P225H": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "V106A,V179E,F227L": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106A,V179E,Y181C,H221Y": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V106A,Y181C": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "V106A,Y181C,F227C": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT227C": "F227C is a nonpolymorphic mutation selected in persons receiving DOR and rarely in persons receiving ETR and RPV. It usually occurs in combination with other DRMs and in this setting has consistently been associated with the highest possible levels of DOR resistance. It is also usually associated with intermediate or higher reductions in susceptibility to NVP, EFV, ETR, and RPV. "
  },
  "V106A,Y181C,F227L": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106A,Y181C,G190A": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V106A,Y181C,G190A,F227L": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106A,Y181C,G190A,H221Y": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V106A,Y181C,G190A,H221Y,F227L": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106A,Y181C,G190A,N348I": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "V106A,Y181C,G190A,P225H": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "V106A,Y181C,G190S,F227L": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106A,Y181C,H221Y": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V106A,Y181C,H221Y,F227L": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106A,Y181C,Y188C": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV."
  },
  "V106A,Y188C": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV."
  },
  "V106A,Y188F": {
    "RT106A": "V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.",
    "RT188F": "Y188F is a rare non-polymorphic NNRTI-associated mutation that is usually present as part of an electrophoretic mixture. It appears to represent a transitional mutation between Y and L."
  },
  "V106I": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. "
  },
  "V106I,E138A": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
  },
  "V106I,E138A,V179D": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "V106I,E138A,Y188L": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "V106I,E138A,Y188L,G190A": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V106I,E138G": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR."
  },
  "V106I,E138G,G190A": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V106I,E138G,Y188L": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "V106I,E138K": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR."
  },
  "V106I,E138Q,Y181C": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "V106I,E138Q,Y188C": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV."
  },
  "V106I,F227C": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT227C": "F227C is a nonpolymorphic mutation selected in persons receiving DOR and rarely in persons receiving ETR and RPV. It usually occurs in combination with other DRMs and in this setting has consistently been associated with the highest possible levels of DOR resistance. It is also usually associated with intermediate or higher reductions in susceptibility to NVP, EFV, ETR, and RPV. "
  },
  "V106I,F227L": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106I,G190A": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V106I,G190A,H221Y": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V106I,G190A,H221Y,F227L": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106I,G190A,N348I": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "V106I,G190A,Y318F": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "V106I,G190S": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "V106I,G190S,M230L": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "V106I,H221Y": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V106I,H221Y,M230L": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "V106I,K238T": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "V106I,M230L": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "V106I,N348I": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "V106I,P225H": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "V106I,V108I": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
  },
  "V106I,V108I,G190A": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V106I,V108I,G190A,H221Y": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V106I,V108I,V179D": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "V106I,V108I,Y181C": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "V106I,V108I,Y181C,G190A": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V106I,V108I,Y181C,H221Y": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V106I,V108I,Y181C,N348I": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "V106I,V108I,Y181I,H221Y": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V106I,V108I,Y181I,M230L": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "V106I,V179D": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "V106I,V179D,G190A": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V106I,V179D,G190A,M230L": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "V106I,V179D,Y181C": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "V106I,V179D,Y181C,G190A": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V106I,V179D,Y188C": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV."
  },
  "V106I,V179D,Y188L": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "V106I,V179D,Y188L,G190E": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190EQ": "G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known."
  },
  "V106I,V179E": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "V106I,V179E,Y181C": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "V106I,V179E,Y181C,Y188L": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "V106I,V179E,Y188C": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV."
  },
  "V106I,V179E,Y188L": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "V106I,V179E,Y188L,H221Y": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V106I,V179E,Y188L,K238N": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "V106I,V179L,Y188L": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT179L": "V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "V106I,V179T,Y181C,G190S": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT179T": "V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "V106I,Y181C": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "V106I,Y181C,F227L": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106I,Y181C,G190A": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V106I,Y181C,G190A,F227I": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106I,Y181C,G190A,H221Y": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V106I,Y181C,G190A,H221Y,F227L": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106I,Y181C,G190A,N348I": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "V106I,Y181C,G190S": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "V106I,Y181C,G190S,F227L": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106I,Y181C,G190S,H221Y": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V106I,Y181C,H221Y": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V106I,Y181C,H221Y,F227L": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106I,Y181C,H221Y,N348I": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "V106I,Y181C,N348I": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "V106I,Y181C,Y188L": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "V106I,Y181C,Y188L,F227L": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106I,Y181C,Y188L,G190A": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V106I,Y181C,Y188L,G190A,N348I": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "V106I,Y181C,Y188L,H221Y": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V106I,Y181C,Y188L,M230L": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "V106I,Y181C,Y188L,N348I": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "V106I,Y181C,Y318F": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "V106I,Y181C,Y318F,N348I": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "V106I,Y181I": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized."
  },
  "V106I,Y181I,H221Y": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V106I,Y181V": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized."
  },
  "V106I,Y188C": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV."
  },
  "V106I,Y188C,F227L": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106I,Y188F": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT188F": "Y188F is a rare non-polymorphic NNRTI-associated mutation that is usually present as part of an electrophoretic mixture. It appears to represent a transitional mutation between Y and L."
  },
  "V106I,Y188H": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV."
  },
  "V106I,Y188H,G190A": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V106I,Y188L": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "V106I,Y188L,G190A": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V106I,Y188L,H221Y": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V106I,Y188L,H221Y,F227C": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227C": "F227C is a nonpolymorphic mutation selected in persons receiving DOR and rarely in persons receiving ETR and RPV. It usually occurs in combination with other DRMs and in this setting has consistently been associated with the highest possible levels of DOR resistance. It is also usually associated with intermediate or higher reductions in susceptibility to NVP, EFV, ETR, and RPV. "
  },
  "V106I,Y188L,H221Y,N348I": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "V106I,Y188L,K238N": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "V106I,Y188L,K238T": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "V106I,Y188L,L234I": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT234I": "L234I is a nonpolymorphic mutation selected in persons receiving NVP and EFV. It is also selected in vitro by ETR and DOR. In combination with V106A, it is associated with high-level DOR resistance. Its effect on susceptibility when it occurs alone has not been studied."
  },
  "V106I,Y188L,N348I": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "V106I,Y188L,Y318F": {
    "RT106I": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. ",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "V106M": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "V106M,E138A": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
  },
  "V106M,E138A,F227L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106M,E138A,F227L,M230L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "V106M,E138A,G190A": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V106M,E138A,H221Y": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V106M,E138A,M230L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "V106M,E138A,V179D": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "V106M,E138A,V179D,F227L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106M,E138A,V179D,G190A": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V106M,E138A,V179D,K238T": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "V106M,E138A,V179D,M230L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "V106M,E138A,V179E": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "V106M,E138A,V179E,F227L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106M,E138A,V179E,H221Y,F227L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106M,E138A,V179E,Y181C,G190A,H221Y": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V106M,E138A,Y181C,F227L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106M,E138A,Y188C": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV."
  },
  "V106M,E138A,Y188C,H221Y,F227L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106M,E138G,F227L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106M,E138G,V179D": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "V106M,E138K": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR."
  },
  "V106M,E138K,F227L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106M,E138K,H221Y,F227L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106M,E138K,M184I": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT184VI": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
  },
  "V106M,E138K,Y188L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "V106M,E138Q": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR."
  },
  "V106M,E138Q,G190A": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V106M,E138Q,H221Y,F227C": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227C": "F227C is a nonpolymorphic mutation selected in persons receiving DOR and rarely in persons receiving ETR and RPV. It usually occurs in combination with other DRMs and in this setting has consistently been associated with the highest possible levels of DOR resistance. It is also usually associated with intermediate or higher reductions in susceptibility to NVP, EFV, ETR, and RPV. "
  },
  "V106M,E138Q,V179D": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "V106M,E138R": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT138R": "E138R is a rare non-polymorphic accessory mutation selected in vitro by RPV. It is associated with 2 to 3-fold reduced susceptibility to ETR and RPV."
  },
  "V106M,F227L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106M,F227L,M230L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "V106M,G190A": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V106M,G190A,F227L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106M,G190A,F227L,M230L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "V106M,G190A,H221Y": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V106M,G190A,H221Y,F227I,M230L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "V106M,G190A,H221Y,F227L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106M,G190A,K238N": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "V106M,G190A,M230L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "V106M,G190A,N348I": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "V106M,H221Y,F227C": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227C": "F227C is a nonpolymorphic mutation selected in persons receiving DOR and rarely in persons receiving ETR and RPV. It usually occurs in combination with other DRMs and in this setting has consistently been associated with the highest possible levels of DOR resistance. It is also usually associated with intermediate or higher reductions in susceptibility to NVP, EFV, ETR, and RPV. "
  },
  "V106M,H221Y,F227L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106M,H221Y,F227L,M230L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "V106M,K238N": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "V106M,M230L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "V106M,V108I": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
  },
  "V106M,V108I,E138A,V179D": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "V106M,V108I,F227L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106M,V108I,F227L,M230L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "V106M,V108I,G190A": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V106M,V108I,G190A,F227L,M230L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "V106M,V108I,V179D,F227L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106M,V108I,V179D,M230L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "V106M,V108I,V179E,F227L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106M,V108I,Y181C,H221Y": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V106M,V108I,Y181C,H221Y,F227L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106M,V108I,Y188C": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV."
  },
  "V106M,V108I,Y188L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "V106M,V179D": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "V106M,V179D,F227L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106M,V179D,F227L,M230L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "V106M,V179D,F227L,Y318F": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "V106M,V179D,G190A": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V106M,V179D,G190A,F227L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106M,V179D,H221Y": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V106M,V179D,H221Y,F227L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106M,V179D,M230L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "V106M,V179D,Y181C": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "V106M,V179D,Y181C,G190A": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V106M,V179D,Y188C": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV."
  },
  "V106M,V179D,Y188L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "V106M,V179E": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "V106M,V179E,F227L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106M,V179E,G190A": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V106M,V179E,G190A,F227L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106M,V179E,N348I": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "V106M,V179E,Y181C,F227L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106M,V179E,Y181C,G190A": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V106M,V179E,Y188L,G190A": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V106M,V179T,Y181C,G190A": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT179T": "V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V106M,Y181C": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "V106M,Y181C,F227L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106M,Y181C,G190A": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V106M,Y181C,G190A,F227L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106M,Y181C,G190A,H221Y": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V106M,Y181C,G190S": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "V106M,Y181C,H221Y": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V106M,Y181C,H221Y,F227L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106M,Y181C,M230L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "V106M,Y181C,Y188L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "V106M,Y181I,G190A,F227L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106M,Y181V,G190A,F227L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106M,Y188C": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV."
  },
  "V106M,Y188C,G190A": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V106M,Y188C,H221Y": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V106M,Y188C,M230L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "V106M,Y188C,N348I": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "V106M,Y188F,F227L,M230L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT188F": "Y188F is a rare non-polymorphic NNRTI-associated mutation that is usually present as part of an electrophoretic mixture. It appears to represent a transitional mutation between Y and L.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "V106M,Y188H": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV."
  },
  "V106M,Y188H,F227L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106M,Y188H,M230L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "V106M,Y188L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "V106M,Y188L,F227L": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V106M,Y188L,G190A": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V106M,Y188L,H221Y": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V106M,Y188L,K238N": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "V106M,Y188L,N348I": {
    "RT106M": "V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "V108I": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
  },
  "V108I,E138A": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
  },
  "V108I,E138A,V179D,Y181C,H221Y": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V108I,E138A,Y181C,G190A": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V108I,E138A,Y181I": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138A": "E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized."
  },
  "V108I,E138G": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR."
  },
  "V108I,E138G,Y181I": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized."
  },
  "V108I,E138K": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR."
  },
  "V108I,E138K,G190A": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V108I,E138K,G190A,H221Y,F227L": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V108I,E138K,M184I": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138K": "E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR.",
    "RT184VI": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
  },
  "V108I,E138Q,Y181C,H221Y": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V108I,E138Q,Y181C,H221Y,F227L": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V108I,E138Q,Y181C,H221Y,F227L,N348I": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT138QG": "E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "V108I,F227L": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V108I,F227L,N348I": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "V108I,G190A": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V108I,G190A,F227L": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V108I,G190A,F227L,M230L": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "V108I,G190A,H221Y": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V108I,G190A,H221Y,F227L": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V108I,G190A,H221Y,F227L,M230L": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "V108I,G190E": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190EQ": "G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known."
  },
  "V108I,G190S": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "V108I,G190S,F227L": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V108I,H221Y": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V108I,H221Y,F227L": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V108I,H221Y,K238T": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "V108I,H221Y,N348I": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "V108I,K238N": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "V108I,K238N,Y318F": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "V108I,K238T": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "V108I,M230I": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT230I": "M230I is an extremely rare mutation selected by RPV. Its effects on NNRTI susceptibility have not been well studied. It also often occurs as a result of APOBEC-mediated G-to-A hypermutation resulting in viruses that are likely to be noninfectious."
  },
  "V108I,N348I": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "V108I,V179D": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "V108I,V179D,G190A": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V108I,V179D,Y181C": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "V108I,V179D,Y181C,G190A": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V108I,V179D,Y181C,G190A,H221Y,F227L": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V108I,V179D,Y181C,H221Y": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V108I,V179D,Y181I,F227L,N348I": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "V108I,V179E": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "V108I,V179E,G190A": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V108I,V179E,H221Y": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V108I,V179E,M230L": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "V108I,V179E,Y181C": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "V108I,V179E,Y181C,G190A,H221Y": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V108I,V179E,Y181C,G190A,K238T": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "V108I,V179E,Y181C,H221Y": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V108I,V179E,Y181C,M230L": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "V108I,V179E,Y181G": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181FSG": "Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V."
  },
  "V108I,V179E,Y188L": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "V108I,V179F,Y181C,G190A": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179F": "V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V108I,V179F,Y181C,H221Y": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179F": "V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V108I,V179T,Y181C": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179T": "V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "V108I,V179T,Y181C,H221Y": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT179T": "V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V108I,Y181C": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "V108I,Y181C,F227L": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V108I,Y181C,G190A": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V108I,Y181C,G190A,F227L": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V108I,Y181C,G190A,H221Y": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V108I,Y181C,G190A,H221Y,F227L": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V108I,Y181C,G190A,H221Y,K238N": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "V108I,Y181C,G190A,H221Y,K238T": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "V108I,Y181C,G190A,K238T": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "V108I,Y181C,G190A,N348I": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "V108I,Y181C,G190S": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "V108I,Y181C,G190S,F227L": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V108I,Y181C,G190S,H221Y": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V108I,Y181C,H221Y": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V108I,Y181C,H221Y,F227I": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V108I,Y181C,H221Y,F227L": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V108I,Y181C,H221Y,K238N": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "V108I,Y181C,H221Y,K238T": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "V108I,Y181C,H221Y,M230L": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "V108I,Y181C,H221Y,N348I": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "V108I,Y181C,K238N": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "V108I,Y181C,K238T": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "V108I,Y181C,M230L": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "V108I,Y181C,N348I": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "V108I,Y181C,Y188H": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV."
  },
  "V108I,Y181C,Y188L": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "V108I,Y181C,Y188L,G190A": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V108I,Y181C,Y188L,G190S": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "V108I,Y181C,Y318F": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "V108I,Y181F": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181FSG": "Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V."
  },
  "V108I,Y181G,G190A,H221Y": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181FSG": "Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V108I,Y181I": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized."
  },
  "V108I,Y181I,H221Y": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V108I,Y181I,N348I": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "V108I,Y181S,G190A": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181FSG": "Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V108I,Y181V": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized."
  },
  "V108I,Y181V,G190A,H221Y": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V108I,Y181V,H221Y": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V108I,Y181V,N348I": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "V108I,Y188L": {
    "RT108I": "V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "V179D": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "V179D,F227L": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V179D,G190A": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V179D,G190A,K238T": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "V179D,G190A,M230L": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "V179D,G190A,M230L,K238T": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "V179D,G190A,N348I": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "V179D,G190A,P225H": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "V179D,G190Q": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190EQ": "G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known."
  },
  "V179D,G190S": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "V179D,G190S,N348I": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "V179D,K238T": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "V179D,M230L": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "V179D,N348I": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "V179D,Y181C": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "V179D,Y181C,G190A": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V179D,Y181C,G190A,F227L": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "V179D,Y181C,G190A,K238T": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "V179D,Y181C,G190A,P225H": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "V179D,Y181C,G190S": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "V179D,Y181C,H221Y": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V179D,Y181C,H221Y,M230L": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "V179D,Y181C,H221Y,N348I": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "V179D,Y181C,H221Y,Y318F": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "V179D,Y181C,N348I": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "V179D,Y181C,Y188H": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV."
  },
  "V179D,Y181C,Y188L": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "V179D,Y181C,Y188L,G190A": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V179D,Y181I": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized."
  },
  "V179D,Y181I,G190A": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V179D,Y188C,G190A": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V179D,Y188H": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV."
  },
  "V179D,Y188L": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "V179D,Y188L,H221Y": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V179D,Y188L,P225H": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "V179E": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen."
  },
  "V179E,G190A": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V179E,G190A,H221Y": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V179E,G190A,N348I": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "V179E,G190S": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "V179E,H221Y": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V179E,H221Y,P225H,M230L,K238T": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "V179E,M230L": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "V179E,Y181C": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "V179E,Y181C,G190A": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V179E,Y181C,G190S": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "V179E,Y181C,H221Y": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V179E,Y181C,N348I": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "V179E,Y181C,Y188L": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "V179E,Y181I,G190A": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V179E,Y181I,N348I": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "V179E,Y181V,G190A": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V179E,Y188H": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV."
  },
  "V179E,Y188L": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "V179E,Y188L,G190A": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V179E,Y188L,H221Y": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V179E,Y188L,N348I": {
    "RT179DE": "V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "V179F": {
    "RT179F": "V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
  },
  "V179F,Y181C,G190A": {
    "RT179F": "V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V179F,Y181C,G190A,H221Y": {
    "RT179F": "V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V179F,Y181C,G190S": {
    "RT179F": "V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "V179F,Y181C,G190S,K238T": {
    "RT179F": "V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "V179F,Y181C,H221Y": {
    "RT179F": "V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V179L": {
    "RT179L": "V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert."
  },
  "V179L,G190A": {
    "RT179L": "V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V179L,Y181C": {
    "RT179L": "V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "V179L,Y181C,G190A": {
    "RT179L": "V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V179L,Y181C,H221Y": {
    "RT179L": "V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "V179L,Y181I": {
    "RT179L": "V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert.",
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized."
  },
  "V179L,Y188L": {
    "RT179L": "V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "V179L,Y188L,Y318F": {
    "RT179L": "V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "V179T,Y181C": {
    "RT179T": "V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "V179T,Y181C,G190A": {
    "RT179T": "V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "V179T,Y181C,G190C": {
    "RT179T": "V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190CTV": "G190C/T/V are rare non-polymorphic mutations that cause high-level resistance to NVP and EFV. Their effects on ETR, RPV, and DOR susceptibility are not known."
  },
  "V179T,Y181C,G190S": {
    "RT179T": "V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "V179T,Y181C,N348I": {
    "RT179T": "V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "V179T,Y181C,Y188C,G190A": {
    "RT179T": "V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score.",
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "Y181C": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
  },
  "Y181C,F227L": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "Y181C,F227V": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "Y181C,G190A": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "Y181C,G190A,F227L": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "Y181C,G190A,H221Y": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "Y181C,G190A,H221Y,F227L": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "Y181C,G190A,H221Y,K238T": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "Y181C,G190A,K238T": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "Y181C,G190A,N348I": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "Y181C,G190A,P225H": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "Y181C,G190A,P225H,K238T": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "Y181C,G190A,Y318F": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "Y181C,G190C": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190CTV": "G190C/T/V are rare non-polymorphic mutations that cause high-level resistance to NVP and EFV. Their effects on ETR, RPV, and DOR susceptibility are not known."
  },
  "Y181C,G190E,H221Y": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190EQ": "G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "Y181C,G190Q,N348I": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190EQ": "G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "Y181C,G190S": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "Y181C,G190S,H221Y": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "Y181C,G190S,K238T": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "Y181C,G190S,N348I": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "Y181C,G190S,P225H": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "Y181C,G190T": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190CTV": "G190C/T/V are rare non-polymorphic mutations that cause high-level resistance to NVP and EFV. Their effects on ETR, RPV, and DOR susceptibility are not known."
  },
  "Y181C,G190T,H221Y": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190CTV": "G190C/T/V are rare non-polymorphic mutations that cause high-level resistance to NVP and EFV. Their effects on ETR, RPV, and DOR susceptibility are not known.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "Y181C,G190T,K238T": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT190CTV": "G190C/T/V are rare non-polymorphic mutations that cause high-level resistance to NVP and EFV. Their effects on ETR, RPV, and DOR susceptibility are not known.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "Y181C,H221Y": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "Y181C,H221Y,F227L": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "Y181C,H221Y,K238N": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "Y181C,H221Y,K238T": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "Y181C,H221Y,M230L": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "Y181C,H221Y,N348I": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "Y181C,H221Y,P225H": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "Y181C,K238N": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "Y181C,K238T": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "Y181C,M230L": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "Y181C,N348I": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "Y181C,P225H": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "Y181C,Y188C": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV."
  },
  "Y181C,Y188C,G190A": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "Y181C,Y188C,G190A,M230L": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "Y181C,Y188C,H221Y": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "Y181C,Y188C,M230L": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "Y181C,Y188F": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188F": "Y188F is a rare non-polymorphic NNRTI-associated mutation that is usually present as part of an electrophoretic mixture. It appears to represent a transitional mutation between Y and L."
  },
  "Y181C,Y188H,G190A": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "Y181C,Y188H,H221Y": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "Y181C,Y188L": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "Y181C,Y188L,G190A": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "Y181C,Y188L,G190A,H221Y": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "Y181C,Y188L,H221Y": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "Y181C,Y188L,K238N": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "Y181C,Y318F": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "Y181C,Y318F,N348I": {
    "RT181C": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by \u003e50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "Y181F": {
    "RT181FSG": "Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V."
  },
  "Y181F,H221Y": {
    "RT181FSG": "Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "Y181F,Y188L": {
    "RT181FSG": "Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "Y181G": {
    "RT181FSG": "Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V."
  },
  "Y181G,G190A": {
    "RT181FSG": "Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "Y181G,G190A,N348I": {
    "RT181FSG": "Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "Y181G,H221Y": {
    "RT181FSG": "Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "Y181G,Y188L,G190A": {
    "RT181FSG": "Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "Y181I": {
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized."
  },
  "Y181I,G190A": {
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "Y181I,G190C": {
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT190CTV": "G190C/T/V are rare non-polymorphic mutations that cause high-level resistance to NVP and EFV. Their effects on ETR, RPV, and DOR susceptibility are not known."
  },
  "Y181I,G190E": {
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT190EQ": "G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known."
  },
  "Y181I,G190S": {
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "Y181I,H221Y": {
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "Y181I,M230L": {
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "Y181I,N348I": {
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "Y181I,Y188F": {
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT188F": "Y188F is a rare non-polymorphic NNRTI-associated mutation that is usually present as part of an electrophoretic mixture. It appears to represent a transitional mutation between Y and L."
  },
  "Y181S": {
    "RT181FSG": "Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V."
  },
  "Y181S,G190A": {
    "RT181FSG": "Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "Y181S,H221Y": {
    "RT181FSG": "Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "Y181S,Y188L": {
    "RT181FSG": "Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "Y181V": {
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized."
  },
  "Y181V,G190A": {
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "Y181V,G190S": {
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "Y181V,H221Y": {
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "Y181V,K238T": {
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "Y181V,N348I": {
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "Y181V,P225H": {
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "Y181V,Y188L,G190C": {
    "RT181IV": "Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190CTV": "G190C/T/V are rare non-polymorphic mutations that cause high-level resistance to NVP and EFV. Their effects on ETR, RPV, and DOR susceptibility are not known."
  },
  "Y188C": {
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV."
  },
  "Y188C,G190A": {
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "Y188C,G190S": {
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "Y188C,H221Y": {
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "Y188C,M230L": {
    "RT188C": "Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "Y188F": {
    "RT188F": "Y188F is a rare non-polymorphic NNRTI-associated mutation that is usually present as part of an electrophoretic mixture. It appears to represent a transitional mutation between Y and L."
  },
  "Y188F,H221Y": {
    "RT188F": "Y188F is a rare non-polymorphic NNRTI-associated mutation that is usually present as part of an electrophoretic mixture. It appears to represent a transitional mutation between Y and L.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "Y188H": {
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV."
  },
  "Y188H,G190S": {
    "RT188H": "Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "Y188L": {
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
  },
  "Y188L,F227L": {
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "Y188L,G190A": {
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
  },
  "Y188L,G190A,H221Y": {
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "Y188L,G190A,N348I": {
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190A": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "Y188L,G190E": {
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190EQ": "G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known."
  },
  "Y188L,G190S": {
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT190S": "G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
  },
  "Y188L,H221Y": {
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C."
  },
  "Y188L,H221Y,F227L": {
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT227ILV": "F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
  },
  "Y188L,H221Y,L234I": {
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT221Y": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.",
    "RT234I": "L234I is a nonpolymorphic mutation selected in persons receiving NVP and EFV. It is also selected in vitro by ETR and DOR. In combination with V106A, it is associated with high-level DOR resistance. Its effect on susceptibility when it occurs alone has not been studied."
  },
  "Y188L,K238N": {
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "Y188L,K238T": {
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
  },
  "Y188L,K238T,N348I": {
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT238TN": "K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "Y188L,M230L": {
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT230L": "M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
  },
  "Y188L,N348I": {
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT348I": "N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold."
  },
  "Y188L,P225H": {
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT225H": "P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
  },
  "Y188L,Y318F": {
    "RT188L": "Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  },
  "Y318F": {
    "RT318F": "Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied."
  }
}